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CHAPTER I 
 
INTRODUCTION1 
 
Respiration 
 In respiration, organisms catalyze diverse oxidation-reduction reactions, first, to 
establish a transmembrane electrochemical gradient, and second, to use this 
energy to form ATP with the ATP synthase (77). Aerobic respiration uses O2 as the 
terminal electron acceptor (Fig. 1a) and is the most energy-efficient respiration 
pathway (108). Anaerobic respiration can use a variety of small inorganic and 
organic molecules as terminal electron acceptors, although these pathways result in 
lowered ATP levels for the cell. Compounds utilized include sulfate (13), nitrate (39, 
40), nitrite (53), and organic acceptors such as fumarate (Fig. 1b) (113). In 
Escherichia coli, aerobic and anaerobic respiration converge on the chemical 
interconversion of succinate and fumarate. Anaerobic respiration can use a variety 
of small inorganic and organic molecules as terminal electron acceptors, although 
these pathways result in lowered ATP levels for the cell. Compounds utilized  
 
 
 
1Copyright © American Society for Microbiology, Tomasiak, T.M., Cecchini, G., and 
Iverson, T.M. 13 August 2007, posting date. Chapter 3.2.6, Succinate as Donor; 
Fumarate as Acceptor. in A. Böck, R. Curtiss III, J. B. Kaper, F. C. Neidhardt, T. 
Nyström, J. M. Slauch, and C. L. Squires (ed.), EcoSal—Escherichia coli and 
Salmonella: cellular and molecular biology. http://www.ecosal.org. ASM Press, 
Washington, D.C. (2007). 
 
 
 2 
include sulfate (13), nitrate (39, 40), nitrite (53), and organic acceptors such as 
fumarate (Fig. 1b) (113). In Escherichia coli, aerobic and anaerobic respiration 
converge on the chemical interconversion of succinate and fumarate. 
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Figure 1. The aerobic and anaerobic respiratory chains. (a) Aerobic respiratory 
chain. In aerobic respiration, reduced ubiquinol passes electrons from upstream reductases 
such as SQR and NADH oxidase I (98, 115) to cytochrome bo3 oxidase  and ultimately to 
oxygen (1, 18, 91). Cytochrome bd oxidase, omitted for clarity, is expressed at levels similar 
to those of cytochrome bo3 oxidase under microaerophilic conditions (30). NDH-I also 
participates in anaerobic respiration (110). (b) Anaerobic respiratory chain. In anaerobic 
respiration, reduced menaquinol passes electrons from hydrogenase-2 (73, 97) and 
anaerobic 3-phosphate dehydrogenase (21, 41) to terminal oxidases such as QFR. 
Succinate (Fig. 2a) is used as an electron donor during aerobic respiration (by oxidation to 
fumarate), while fumarate (Fig. 2b) is reduced to succinate during anaerobic respiration as a 
terminal electron acceptor (35, 108).  
 4 
 
 
Figure 2. Succinate (a) and fumarate (b). Succinate  and fumarate are sterically 
similar dicarboxylate molecules that are interconverted through a two-proton, two-electron 
transition.  
 
 
In E. coli the oxido-reduction of fumarate and succinate is linked to a second 
oxidation-reduction reaction of the membrane-soluble small molecule quinones (Fig. 
3). Since quinones are membrane embedded, the respiratory complexes coupling 
succinate-fumarate interconversion to quinone-quinol interconversion are integral 
membrane proteins. It was previously demonstrated that two distinct enzymes 
interconvert fumarate and succinate in E. coli (35).  
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Figure 3. Menaquinol and ubiquinol. Like succinate and fumarate, quinol (a and c) 
and quinone (b and d) are interconverted with a two-proton, two-electron transition, making 
the coupling of succinate/fumarate to quinol/quinone energetically well matched. 
Specifically, interconversion between quinol and quinone occurs at the hydroxyl/carbonyl, 
highlighted in red. (a and b) Ubiquinol and ubiquinone interconversion. (c and d) Menaquinol 
and menaquinone interconversion. 
 
 
Succinate:quinone oxidoreductase (SQR, also termed succinate dehydrogenase or 
Complex II in mitochondria) is an essential component of the tricarboxylic acid cycle 
in aerobically grown prokaryotic and eukaryotic cells, in which it oxidizes succinate to 
 6 
fumarate coupled to the reduction of ubiquinone. The enzyme is encoded by the 
sdhCDAB operon (Fig. 4). During anaerobic respiration, in many 
prokaryotes and lower eukaryotes, the structurally related enzyme quinol:fumarate 
reductase (QFR, also termed fumarate reductase) oxidizes menaquinol in the 
membrane domain and reduces fumarate to succinate in the cytoplasm. QFR is also 
encoded by a compact operon, but the gene order is frdABCD (Fig. 4).  
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Figure 4. Comparison of SQR and QFR structures. Both SQR (a) and QFR (b) 
comprise four polypeptide subunits: a flavoprotein subunit (blue: sdhA, SQR; frdA, QFR), an 
iron protein subunit (orange: sdhB, SQR; frdB, QFR), and two transmembrane subunits 
(green [sdhC, SQR; frdC, QFR] and purple [sdhD, SQR; frdD, QFR]). The respective genes 
of QFR and SQR comprise two distinct operons with different gene order. The genes are 
shown in the same color scheme as the structures. Standard nomenclature uses the chain 
name in addition to the residue number in identifying an amino acid.  
 
 
Respiratory Roles of QFR and SQR 
E. coli, as a facultative anaerobe, grows readily in aerobic, microaerophilic, or 
anaerobic environments. To accomplish this feat, the organism has developed an 
elaborate mechanism to control expression of metabolic enzymes used in catabolic 
and anabolic pathways, mainly at the transcriptional level (95, 96, 100). The 
 8 
transcription of both the SQR and QFR respiratory complexes is controlled by the 
availability of O2 (42, 49, 61). SQR is highly expressed in the presence  
of O2, whereas QFR is expressed under anaerobic or microaerophilic conditions. As 
a result, the level of one enzyme is usually predominant, depending on growth 
conditions. SQR levels rise in the presence of oxygen due to deactivation of the 
repressor ArcB (42) by the oxygen-sensitive kinase ArcA (43) (see chapter 3.2.10). 
In contrast, the fumarate-nitrate reductase regulator (FNR) controls QFR levels (56) 
by forming a dimer (61) that activates transcription when oxygen levels fall (see 
chapters 3.2.10 and 3.4.5).  
 During aerobic respiration, SQR oxidizes succinate to fumarate 
(succinate/fumarate couple Εm7= +30 mV [32]) and transfers two electrons and two 
protons to ubiquinone (Εm7 UQ/UQH2 = +90 mV [84]), reducing it to ubiquinol (UQH2). 
Both ubiquinone and ubiquinol are freely diffusible within the membrane. After 
dissociation of UQH2 from SQR, the quinol is transferred to downstream oxidases 
(12, 91) (see chapter 3.2.5 for more details), where reoxidation of quinol by the 
cytochrome bd or bo3 quinol oxidases provides input electrons for further 
downstream reactions. Transmembrane oxido-reduction of quinones is also a 
general mechanism of generating a transmembrane electrochemical potential (77); 
however, the oxidation of succinate by SQR does not result in any charge separation 
across the membrane, and so SQR is not a proton pump and enzyme activity is not 
affected by membrane potential (Fig. 5). It has been suggested that this is the case 
in both E. coli and mitochondrial SQR because the electron transfer reactions are 
not sufficiently exergonic to promote proton translocation (102). There are cases of 
 9 
di-heme SQRs, such as that from Bacillus subtilis, which use menaquinone as a 
substrate and do not undergo endergonic electron transport that responds to the 
membrane proton or electrochemical potential (99). These di-heme SQRs are found 
in gram-positive bacteria, are succinate-menaquinone oxidoreductases, and are 
classified differently than E. coli SQR. Their properties have been reviewed 
elsewhere (32, 57, 65).  
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Figure 5. Comparison of Q-cycle-like proton gradient formation and the electro-
neutral reactions of SQR. (a) Mitchellian loop and proton gradient formation. Two coupled 
reactions on opposite sides of the membrane (labeled with stars)—uptake protons on one 
side of the membrane and release protons on the other. This results in a net separation of 
two protons and establishment of a proton gradient. (b) Non-Mitchellian loop in SQR. SQR 
and QFR catalyze two reactions with proton release and uptake on the same side of the 
membrane, resulting in no net charge displacement. 
  
 
QFR catalyzes the reverse reaction of SQR, namely, the reduction of fumarate to 
succinate (succinate/fumarate couple Εm7 = +30 mV [32]) coupled to menaquinol (Εm7 
MQ/MQH2 = −74 mV) oxidation (108, 113). This reaction is the final step in anaerobic 
respiration with fumarate. During anaerobic respiration with fumarate, the 
transmembrane proton gradient is established by respiratory complexes upstream of 
 11 
QFR, such as formate dehydrogenase (120), hydrogenase (50), and glycerol-3-
phosphate dehydrogenase (55, 76) (see chapters 3.2.2 and 3.2.7). The contribution 
that QFR makes to the transmembrane gradient is thus indirect since it couples the 
reoxidation of MQH2 to MQ to fumarate reduction (35, 55). This generates oxidizing 
equivalents for other respiratory complexes (59). As for E. coli SQR, this is most 
easily explained by the fact that the fumarate reduction site is in the cytoplasm and 
the menaquinol oxidation site is at the membrane cytoplasmic interface. Thus, 
protons released by menaquinol oxidation and fumarate reduction balance each 
other and remain in the cytoplasm and no net proton gradient is produced. The E. 
coli QFR is different in this aspect from di-heme-containing QFRs, such as those 
from Wolinella succinogenes, as discussed in a series of interesting articles from the 
Lancaster laboratory (55, 57, 65).  
 
 
Subunit architecture and function 
Despite opposite catalytic directions under normal physiological conditions, QFR 
and SQR have similar molecular weights (20, 22, 24, 63, 119) and architecture (44, 
121), contain nearly identical sets of cofactors, can catalyze succinate-fumarate 
interconversion bi-directionally in vitro (Table 1), and can functionally replace one 
another in vivo (31, 66). SQR and QFR contain four nonidentical subunits, and the 
enzymes can be divided into hydrophilic and hydrophobic domains (Fig. 4). The 
hydrophilic subunits A and B of both enzymes are sufficient for the succino-oxidase/ 
fumarate reductase activities of the enzymes with artificial electron acceptors. These 
 12 
domains are often referred to as the succinate dehydrogenase and fumarate 
reductase portions of SQR and QFR, respectively. The hydrophobic membrane 
anchor domain subunits C and D are necessary to confer the quinone 
oxidoreductase activity to both SQR and QFR. Although both enzymes are bi-
directional in that they readily oxidize succinate or reduce fumarate, they are poised 
to function differently in vivo. As is shown in Table 1, SQR—in catalytic assays 
using artificial electron donors/acceptors —is 50-fold more efficient as a succino-
oxidase than it is as a fumarate reductase. 
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Enzym
e 
Succinate oxidation Fumarate 
reduction 
Catalytic efficiency 
(kcat/km) 
kcat 
(succinate
/s−1) 
kmsuc
c 
(µM) 
kiOAA 
(µM) 
kcat 
(fumarate
/s−1) 
kmfum 
(µM) 
Succinate 
oxidase 
Fumarate 
reductase 
SQR 110 110 0.07 2 100 1,000 20 
QFR 30 550 0.3 250 20 54 232 
Table 1. Catalytic parameters for succinate oxidase and fumarate reductase reactions 
catalyzed by E. coli SQR and QFRa 
 
aEnzyme activity was determined on purified enzymes as described in reference 69. 
Enzyme activity was measured by established procedures at 30°C, pH 8.0. For succinate 
oxidase activity of either SQR or QFR, the activity was measured as the decrease in 
absorbance at 600 nm in the presence of succinate, 1.5 mM phenazine ethosulfate (PES), 
and 50 µM 2,6-dichloroindophenol (DCIP) (ε600 = 21.8 mM−1 cm−1) and 20 mM succinate. 
Fumarate reductase activity with the low-potential donor benzylviologen (BV) (Εm7 = −359 
mV) was performed in a cuvette continuously flushed with argon, and the BV was reduced 
by the addition of a stoichiometric amount of sodium dithionite so that the initial OD602 was 
approximately 1.8. To maintain anaerobiosis prior to initiating the reaction, 10 mM glucose, 
glucose oxidase, and catalase were added to the assay cuvette. The reaction was initiated 
by adding either enzyme or 10 mM fumarate to the assay cuvette. Progress of the assay 
was followed by monitoring the decrease in absorbance at 602 nm (ε602 = 9.6 mM−1 cm−1) in 
a UV/VIS spectrophotometer equipped with a temperature-controlled cuvette. 
 
 
Conversely, QFR is only fivefold more efficient as a fumarate reductase than it is as 
a succino-oxidase. The enzymes are, however, physiologically quinone 
oxidoreductases, but the situation is a little more complicated in trying to directly 
compare catalytic activity for the enzymes with quinones (67). Nevertheless, SQR is 
more efficient at reducing ubiquinone than is QFR, whereas QFR is much more 
efficient at oxidizing menaquinol than is SQR (15, 67). Thus, not surprisingly, the 
enzymes appear to have evolved to function best in their proper ecological niche.  
 
Both SQR and QFR from E. coli are hetero-tetrameric membrane proteins with two 
subunits (sdhA, frdA, flavoprotein subunits; sdhB, frdB, iron-sulfur proteins) forming 
 14 
an extra-membrane domain and two subunits (sdhC, cyt bL [SQR] frdC; and sdhD, 
cyt bS [SQR], frdD) forming an integral-membrane domain (residue numbers retain 
the chain name to prevent confusion). This architecture is optimally designed to 
couple the oxido-reduction of a water-soluble dicarboxylate to a membrane-soluble 
quinone. Spectroscopic and structural studies have revealed the presence of four 
covalently attached cofactors in each complex: a flavin adenine dinucleotide (FAD) 
(51) covalently linked to a histidyl residue, and three iron-sulfur (Fe:S) clusters. The 
covalent linkage of the FAD cofactor to the mammalian mitochondrial SQR was the 
first example of such a linkage to any protein (114), and it was subsequently shown 
that E. coli QFR contained a similar linkage (116). After many years of controversy 
in the 1980s it became clear that three distinct types of iron-sulfur clusters are 
present in both mammalian and prokaryotic SQR and QFR. The history of this 
controversy is elegantly reviewed by Beinert (5), and this article includes many of 
the primary references for determination of the Fe:S composition of SQR and QFR. 
In the case of eukaryotic and E. coli SQR and QFR the Fe:S clusters include a 
[2Fe:2S] 2+,1+ cluster, a [4Fe:4S]2+,1+ cluster, and a [3Fe:4S]1+,0 cluster (Fig. 6). 
It is gratifying that the initial crystal structures of the E. coli enzymes (44, 121) 
confirmed that the assignments for the Fe:S clusters were correct.  
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Figure 6. Representations of the SQR (a) and QFR (b) Fe:S clusters. (a) SQR Fe:S 
clusters. Note the unique ligation of the [2Fe:2S] cluster in SQR due to the replacement of a 
cysteine ligand with Asp-B63. Other iron-ligating residues include Cys-B55, Cys-B60, and 
Cys-B75 to the [2Fe:2S] cluster; Cys-B149, Cys-B152, Cys-B155, and Cys-B216 to the 
[4Fe:4S] cluster; and Cys-B159, Cys-B212, and Cys-B206 to the [3Fe:4S] cluster. (b) QFR 
Fe:S clusters. Iron-ligating residues include Cys-B57, Cys-B62, Cys-B55, and Cys-B77 to 
the [2Fe:2S] cluster; Cys-B148, Cys-B151, Cys-B154, and Cys-B214 to the [4Fe:4S] cluster; 
and Cys-B158, Cys-B204, and Cys-B210 to the [3Fe:4S] cluster. For both clusters, iron 
atoms are purple and sulfur atoms are yellow. The main-chain ribbon and side-chain carbon 
atoms are white.  
 
 
In addition to the covalent flavin and Fe:S centers, SQR (but not E. coli QFR) 
contains a noncovalently bound b-type heme in the membrane-spanning region (52). 
In both enzymes, the FAD located in subunit A is part of the active site for 
dicarboxylate interconversion, and an active site for the interconversion of Q and 
QH2 lies at the cytoplasmic side of the membrane interface and is composed of 
residues from the B, C, and D subunits (44, 121). Analyses of the X-ray structures 
 16 
(Fig. 4) also indicated that the cofactors were arranged linearly with intercofactor 
distances <14 Å (Fig. 7) within the physiological limit of electron transfer reactions 
(86).  
As shown in Fig. 4, the structures also confirm other results from spectroscopic and 
enzymatic studies, notably the overall similarity between SQR and QFR. As 
anticipated, SQR and QFR each adopt similar folds in the soluble domain. Structural 
alignment of the flavoprotein subunit of E. coli SQR and QFR shows a root mean 
square (rms) deviation of 1.44 Å for 535 Cα atoms, while structural alignment of the iron-
sulfur protein reveals an rms deviation of 1.256 Å for 221 Cα atoms.  
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Figure 7. Comparison of cofactor arrangements in SQR and QFR. Each cofactor is 
labeled with its respective midpoint (pH 7) reduction potential, and distances are 
represented as lines. (a) SQR cofactor arrangements in relation to the entire complex. (b) 
QFR cofactor composition in relation to the entire complex. FAD, ubiquinone, and heme b 
are yellow, oxygen is red, nitrogen is blue, phosphate is magenta, and iron is purple. 
Additionally, the FAD adenine ring carbon atoms are gray to distinguish them from flavin. 
Sulfur is yellow and iron is purple in three Fe:S clusters. 
 
 
Subunit A: The Flavoprotein 
 The flavoprotein is the largest subunit in each enzyme: 64 kDa in SQR and 67 
kDa in QFR (20, 119). Of the four subunits in SQR and QFR, the flavoprotein 
exhibits the highest sequence identity between the two enzymes (41% identity and 
58% similarity). The flavoprotein contains a covalently linked FAD (114, 116, 121), 
 18 
which is at the active site for dicarboxylate interconversion. This covalent linkage is 
formed between the Nε atom of an absolutely conserved histidine (His-A45, SQR; His-
A44, QFR) and the C8 atom of the FAD (Fig. 8) ( 114, 116).  
 
 
 
 
Figure 8. FAD 8α to His Nε covalent bond. The covalent bond between the 8α 
carbon of FAD and the Nε of histidine is shown. This is shdA His45 in SQR and frdA His44 
in QFR. 
  
 
Formation of the histidyl-FAD bond presumably is autocatalytic in SQR and QFR 
but requires catalytic turnover of the enzyme to complete the covalent linkage. 
Proposed mechanisms for the covalent attachment of flavins to proteins have been 
reviewed in detail (75), and the architecture of the FAD binding site in SQR and 
QFR is consistent with the autocatalytic iminoquinone methide attachment (27, 28). 
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Thus, mutation of side-chain amino acids that affect binding of dicarboxylate 
substrates to the active site often results in loss of covalent linkage to FAD, as was 
initially shown with QFR (10). Mutations that affect the covalent FAD linkage in 
human SQR have been linked to late-onset neurodegenerative disease (9), and the 
equivalent mutations in the E. coli enzymes (sdhA Arg399 or frdA Arg390) are also 
known to result in enzyme containing noncovalent FAD (16). Covalent attachment 
of FAD is one factor, along with the protein environment, that results in a dramatic 
increase in the reduction potential of the covalent FAD compared with free FAD 
(Εm7 = −220 mV) to ~−70 mV in SQR and ~−55 mV in QFR (2, 10, 26, 89). The rise in 
reduction potential along with other electronic factors affecting the flavin becomes 
crucial for succinate oxidation (10, 26, 75). Site-directed mutants of either SQR or 
QFR that lose covalent linkage to FAD can no longer oxidize succinate but retain 
fumarate reductase ability (10). Soluble homologs of the flavoprotein subunit exist in 
several obligate anaerobes (79, 88); these fumarate reductase enzymes contain a 
noncovalent FAD with a lower reduction potential (79, 92) and are essentially 
unable to oxidize succinate (92). The evolutionary retention of a covalently attached 
FAD in QFR may reflect the in vivo requirement for QFR to oxidize succinate when 
E. coli is switching between anaerobic and aerobic respiration.  
 
The mechanism of succinate-fumarate interconversion in SQR  and QFR 
The interconversion of succinate and fumarate occurs at the dicarboxylate binding 
site of SQR and QFR, as described below. Initial studies of succinate  
oxidation used preparations of succinate dehydrogenase that were not pure, and it 
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was not initially recognized that the complete SQR enzyme was membrane bound. 
Nevertheless, it was shown that mammalian succinate dehydrogenase was a 
reversible enzyme capable of both succino-oxidase and fumarate reductase 
activities (71). Succinate dehydrogenase or fumarate reductase activity is most 
conveniently measured using artificial electron acceptor/donors of appropriate redox 
potential (3, 69, 88). Succinate oxidation by both succinate dehydrogenase and 
fumarate reductase can be spectrophotometrically assayed using primary electron 
acceptors such as phenazine ethosulfate (or phenazine  
methosulfate) (3) coupled with the reduction of 2,6-dichlorophenolindophenol. 
Fumarate reduction by either enzyme can be assayed using reduced viologen dyes 
such as benzyl or methyl viologen (3). Note that, as isolated, succinate 
dehydrogenase and fumarate reductase contain tightly bound inhibitory 
oxaloacetate (OAA) at their dicarboxylate binding site (3). The OAA binds more 
tightly to the oxidized forms of the enzyme than it does to the reduced enzymes  
(2, 3). Thus, to accurately measure the initial rate of succinate oxidation the OAA 
must be removed from the dicarboxylate binding site by “activating” the enzyme in 
the presence of succinate or other weaker binding dicarboxylates, such as 
malonate (2, 3). Since the OAA binds much more weakly to reduced succinate 
dehydrogenase and/or fumarate reductase, it is not necessary to activate the 
enzymes to measure fumarate reduction.  
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Figure 9. Fumarate reduction mechanism. (a) Hydride transfer to fumarate by FAD. 
Bound fumarate forms hydrogen bonds to the side chains of His-A232, His-A355, and Arg-
A390. Reduced FAD transfers a hydride to the C-2 carbon on fumarate in a single step. (b) 
Proton transfer to the carbanion intermediate by Arg-A287 to yield succinate. (c) 
Regeneration of catalytically competent protein. Arg-A287 is reprotonated through a proton 
shuttle consisting of Glu-A245 and Arg-A248. FAD is re-reduced by electrons that are 
transferred from quinol through the Fe:S clusters. How FAD is reprotonated has not been 
determined. 
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The dicarboxylate-interconversion reaction mechanism has been best studied in the 
fumarate reduction direction by using soluble homologs of fumarate reductase from 
Shewanella spp. (80, 92). In E. coli QFR, as in its soluble homologs, fumarate 
reduction proceeds in two steps (Fig. 9). In the first step, the reduced FAD transfers 
a hydride to the double bond of fumarate, forming a carbanion intermediate. The 
hydride transfer is likely to be the rate-determining step (64). In the second step, the 
carbanion intermediate accepts a proton from Arg-A287 (Fig. 9). 
Several highly conserved residues, including His A-242 (SQR)/His-A232 (QFR), 
Glu-A255 (SQR)/Glu-A245 (QFR), Arg A-286 (SQR)/Arg-A287 (QFR), His A-354 
(SQR)/His-A355 (QFR), and Arg A-399 (SQR)/Arg-A390 (QFR), line the active site 
(Fig. 10).  
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Figure 10. The QFR flavoprotein subunit (sdhA, SQR; frdA, QFR) and a close-up of 
the active site. (a) The fumarate binding site in relation to the rest of the flavoprotein. (b) 
Close-up of fumarate active site. Fumarate carbon atoms are magenta, and oxygen atoms 
are red. Carbon atoms of catalytically relevant residues and FAD are yellow, with oxygen 
atoms being red and nitrogen atoms being blue. Hydrogen bonds are represented as 
dashed lines.  
 
 
An elegant combination of site-directed mutagenesis (25, 80, 87, 112) and 
crystallography (107) in the soluble fumarate reductase homologs assigned Arg-
A287 (QFR) as the proton shuttle for the second step of the reaction, while the 
remaining conserved residues are likely responsible for binding of the substrate. A 
number of secondary proton shuttles may provide a pathway for protons between 
the active site and the cytoplasm (Fig. 9) (112).  
 
The local active-site environment facilitates fumarate reduction in many ways. First, 
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hydrogen bonds from Arg-A390 and His-A355 to fumarate create a dipole along the 
fumarate double bond (92). The electrostatic effect induces a δ+ charge on the C3 
carbon of the fumarate double bond, making fumarate more susceptible to hydride 
transfer at this position. Second, twisting of the fumarate double bond (Fig. 11) by 
the protein environment may destabilize π-π overlap  
and raise the fumarate free energy. 
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Figure 11. The QFR active site. Fumarate binds near the reduced FAD. The distance 
between the N5 of the FAD and the C-2 atom of the fumarate is 3.4 Å, while the distance 
from a modeled hydride on FAD and the C-2 atom of fumarate is ~2.9Å. The position of 
fumarate (carbons are magenta) is shown modeled into the active site. In the hydride donor, 
FAD, and proton donor, Arg-A287, carbon atoms are yellow, oxygen atoms are red, and 
nitrogen atoms are blue. The oxidation state of FAD could not be determined 
unambiguously by the crystal structures and is shown here modeled as the reduced state.  
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Structures cocrystallized with fumarate show a twisted conformation for the C2-C3 
double bond (60). Domain rearrangements near the flavoprotein active site may 
stabilize the twisted conformation to facilitate catalysis by forcing fumarate to mimic 
the transition state (58, 92).  
In classical enzymology, the enzyme provides an alternate path to product 
formation, speeding up the reaction in both the backward and forward direction. SQR 
and QFR violate the definition of a classic catalyst. While each enzyme can  
catalyze the opposite reaction in vitro and can functionally replace the other in vivo 
(31, 66), both enzymes are more efficient in one direction than in the other (Table 1). 
So far, two separate pieces of the molecular architecture have been shown to control 
the direction of the reaction. The first is the identity of the side-chain residues near 
the electron transfer cofactors of each enzyme. These side chains tune the reduction 
potentials of each cofactor and control the preferential  
direction of electron transfer through the complex (Fig. 7). In considering the full 
fumarate reduction reaction 2H+ + 2e− + fumarate → succinate, it is clear that electrons 
are one substrate. Since SQR limits the availability of electrons at the active site, fumarate 
reduction is not preferentially catalyzed, even in the presence of fumarate, due to 
limitation of the electron substrate.  
 A second parameter controlling the direction of the reaction in SQR and QFR 
is control of the one-electron reduced flavin semiquinone intermediate during 
enzyme turnover. Electron paramagnetic resonance (EPR) analysis of SQR and 
QFR reveal differences in the FAD flavin semiquinone intermediate during enzyme 
turnover, with the SQR FAD transitioning through anionic flavin semiquinone 
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(FAD•−), while QFR apparently uses a neutral flavin semiquinone (FADH•) (69).  
The side chains within coulombic distance of the FAD may suggest how the flavin 
semiquinone intermediate is controlled. An examination of the environment around 
the FAD in the E. coli SQR and QFR, as well as other homologs, reveals an identical 
residue at a conserved position depending on whether the enzyme is SQR or QFR. 
SQR normally has a glutamine residue (Q50 in E. coli SQR), while the 
preponderance of QFRs have a glutamate (E49 in E. coli QFR) at the equivalent 
position. When the equivalent residues are swapped between SQR and QFR (i.e., 
the glutamine in SQR is switched to a glutamate like that found in QFR and the 
converse mutation is done to QFR), SQR becomes a better fumarate reductase 
while QFR becomes a more efficient succinate oxidase (69). This is explained, in 
part, by the observation that electrostatic differences caused by the γ-carboxylate of 
glutamate or the amide of glutamine shift the redox potential of FAD and the stability of 
the flavin semiquinone radical so that the radical in QFR becomes more like that in 
SQR (37, 69). The change in reduction potential along with the changed stabilization 
of the flavin radical in part accounts for kinetic differences between both enzymes 
and suggests that there is a change in the protonation state of the FAD 
environment. In addition, these studies suggest that the “forward reaction” of each 
enzyme uses a hydride transfer while the “backward reaction” uses a hydrogen 
atom transfer. These differences are not enough, however, to account for all of the 
catalytic changes observed that probably reflect a multitude of subtle changes in the 
flavin environment and dicarboxylate binding site (69).  
 The above observations may relate to another intriguing catalytic difference 
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between SQR and QFR in their respective abilities to reduce fumarate. As with most 
enzymes, fumarate reductase increases its rate of catalysis when there is a greater 
thermodynamic driving force, but succinate dehydrogenase demonstrates an 
unusual behavior termed the “tunnel diode” effect (105). These studies were initially 
done with the mitochondrial succinate dehydrogenase; however, the E. coli enzyme 
shows similar properties (89). It was shown that succinate dehydrogenase is able to 
efficiently catalyze fumarate reduction above a redox potential of approximately −60 
mV (7.0); conversely, below this potential, the rate of catalytic fumarate reduction abruptly 
decreases even though the redox driving force has increased. This effect resembles 
the current-voltage characteristics of a tunnel diode found in electronic circuits. 
Succinate dehydrogenase is an excellent fumarate reductase, yet this activity is 
only found over a narrow range of redox potential. Note that fumarate reductase 
does not demonstrate this behavior, as its activity increases along with its potential 
driving force. The physical principles underlying the tunnel diode effect have not 
been determined but have been suggested to relate to subtle differences in the 
properties of the dicarboxylate binding site of SQR and QFR (89, 105). It is possible 
that the tunnel diode effect may limit fumarate reduction under hypoxic conditions 
and prevent SQR reduction of fumarate during anoxic conditions.  
 
Subunit B: The Iron-Sulfur Protein Subunit 
The iron-sulfur protein subunit comprises two distinct domains and is the second 
largest subunit (26.8 kDa in SQR and 27.0 kDa in QFR). The first domain adopts a 
plant-type ferredoxin fold (type I ferredoxin) and contains the [2Fe:2S] cluster, while  
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Figure 12. Comparisons of the iron-protein subunit fold with a type I and type II ferredoxin. 
(a) The QFR iron-protein subunit and positions of Fe:S clusters. The iron-protein main 
chain is orange. (b) Type I ferredoxin. The type I ferredoxin (yellow) contains a single [2Fe-
2S] cluster. Shown is the type I ferredoxin from Anabaena 7120 (46) (PDB ID 1FRD). (c) 
Type II ferredoxin. The type II ferredoxin (red) contains two clusters, [4Fe:4S] and 
[3Fe:4S], in opposite positions compared with QFR. Shown is the type II ferredoxin from 
Azotobacter vinelandii (29) (PDB ID 1A6L). (d) Superposition of the type I and type II 
ferredoxins and the QFR iron protein subunit. The overlay displays the structural similarity 
between the ferredoxins and the QFR iron protein subunit (light gray). The root mean 
square deviation (RMSD) of atom positions in alignment between the Anabaena 7120 type 
I ferredoxin (46) and QFR is 1.3 Å for 68 Cα atoms, while the RMSD of atom positions in 
the alignment between the A. vinelandii 7Fe ferredoxin (29) and QFR is 1.0 Å for 37 Cα 
atoms. All iron atoms are purple and sulfur atoms are yellow in the iron-sulfur clusters. 
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the second domain adopts a bacteria-type ferredoxin fold (type II ferredoxin) and 
contains both the [3Fe:4S] and the [4Fe:4S] clusters (Fig. 12) (44). The iron protein 
is physically positioned between the dicarboxylate interconversion active site in the 
flavoprotein subunit and the Q—QH2 interconversion active site in the membrane. 
The Fe:S clusters provide a pathway for efficient electron transfer between the two 
active sites of these enzymes. The history of the discovery of Fe:S clusters in SQR 
and QFR is described in an excellent review from Beinert (5). Note that succinate 
dehydrogenase was one of the first proteins known to demonstrate tightly bound iron 
(104). The compositions of the Fe:S clusters of SQR were first identified and 
characterized with EPR spectroscopy in bovine heart mitochondria (6, 7, 85, 94). 
Subsequent studies in E. coli QFR confirmed the same composition of Fe:S clusters 
in this enzyme (47, 48, 78). In mitochondrial SQR, E. coli SQR, and QFR, Fe:S 
cluster irons are coordinated by cysteines in ferredoxin-like sequence motifs with 
the [4Fe:4S] cluster coordinated by a C-X-X-C-X-X-C-X3-C-P motif and the 
[3Fe:4S] cluster coordinated by a C-X5-C-X3-C-P motif (22, 24). In QFR, the 
[2Fe:2S] cluster is coordinated by a C- X4-C-X-X-C-X10-C-P motif. Infrequently, in 
E. coli SQR, the third cysteine of the [2Fe:2S] coordinating motif is replaced by an 
aspartate (24), a unique alteration of this motif in SQRs. Mutation of Cys-B65 in 
QFR to aspartate to mimic the SQR [2Fe:2S] structure had no overall effect on the 
midpoint potential or catalytic activity (117), and it is not known why aspartate is 
found in this position in SQR (Fig. 6).  
 As mentioned above, the reduction potential of the Fe:S clusters is tuned to 
control the availability of electrons at the active site FAD (Fig. 7). All three Fe:S 
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clusters of SQR have higher midpoint potentials (83, 85) than their counterparts in 
QFR, but in both enzymes, the reduction potentials of the [4Fe:4S] cluster is 
unusually low. Prior to the determination of crystal structures, it was speculated that 
this Fe:S cluster could be off-pathway for electron transfer (54). The crystal structure 
reveals that edge-to-edge distances of the [4Fe:4S] cluster to the [2Fe:2S] and 
[3Fe:4S] clusters (Fig. 7) fall within physiological electron transfer ranges (<14Å) 
(86). While the thermodynamic barrier imposed by the low [4Fe:4S] cluster potential 
suggests that electron transfer to the [4Fe:4S] cluster is not rate limiting, site-
directed mutagenesis of E. coliSQR that introduced negative charges near the 
4Fe:4S lowered the potential (by ~70 mV to −285 mV) and decreased catalytic 
turnover by 65% (17). That the [4Fe:4S] cluster of QFR is a direct participant in 
electron transfer reactions had previously been shown by protein film  uanidine ry 
and mutagenic studies of E. coli QFR (37).  
 These studies showed that when the [4Fe:4S] cluster is reduced it results in a 
boost in catalytic rate for fumarate reduction by QFR. This is somewhat reminiscent 
of changes in the electronic properties of the FAD that apparently contribute to the 
tunnel diode properties of SQR in the flavoprotein subunit. These findings are 
consistent with an interpretation in which oxido-reduction of the redox centers has 
direct influence on catalytic rates in both SQR and QFR. 
 
Subunits C and D: The Membrane Subunits 
 The integral membrane subunits of SQR and QFR contain the second active 
site in the enzyme (Q-site), which performs oxido-reduction of the membrane-  
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Figure 13. Comparison of four-helix bundles in the QFR (a and c) and SQR (b and d) 
integral membrane subunits (sdhC, frdC in purple and sdhD, frdD in green). Ribbons shown 
in bold coloring represent the four-helix bundle motif. The remaining helices are shown with 
transparency to differentiate them from the four-helix bundle. Ubiquinone (a), heme (a), and 
menaquinol (b) are yellow. Oxygen atoms are red, nitrogen atoms are blue, and iron is 
orange.  
  
 
Soluble small molecule quinone. In contrast to the soluble subunits of SQR and 
QFR, which share considerable sequence similarity, there is no detectable 
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sequence identity in the integral membrane subunits that contain the Q-site. Despite 
this, the C and D integral membrane subunits of both enzymes each comprise three 
transmembrane helices that come together to form a four-helix bundle structural 
motif (Fig. 13).  
The membrane-spanning subunits of SQR and QFR additionally differ in cofactor 
association. SQR contains a b-type heme, heme b556, which is absent in QFR (Fig. 
14). Each complex also preferentially associates with a different type of quinone 
molecule; in SQR, ubiquinone (Fig. 3b) is used as the physiological electron 
acceptor, while in QFR menaquinol (Fig. 3c) is used as the electron donor.  
 
Note, however, that the Q-binding sites in both QFR and SQR can accommodate 
either ubiquinone or menaquinone molecules as evidenced by both in vivo and in 
vitro studies (31, 66, 69). One explanation of why the enzymes preferentially bind 
one quinone over the other is that the redox potential of the [3Fe:4S] cluster, which 
is the direct electron donor/acceptor for SQR and QFR, respectively, is poised to 
interact preferentially with either the higher potential ubiquinone (+ 90 mV) or the 
lower potential menaquinone (−74 mV). As would be expected for active sites that 
bind different small molecules, the side-chain residues of each Q-site differ to 
optimize the binding of one species (Fig. 15). The location of the Q-site with respect 
to the soluble domain also differs; an alignment of SQR and QFR soluble domains 
results in Q-sites that are positioned 15 Å away (Fig. 14) from each other (121).  
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Figure 14. Comparison of relative Q-binding positions in SQR and QFR. (a) SQR 
ubiquinone binding site. (b) QFR menaquinol binding sites. Only the integral membrane 
domains are shown for clarity (light-gray ribbons). Heme b carbon atoms are yellow, iron 
atoms are brown, ubiquinone carbon atoms are tan, and menaquinol carbon atoms are 
green. In all the molecules, oxygen atoms are red and nitrogen atoms are blue. 
 
 
Ubiquinone binding in SQR 
  It was shown by EPR spectroscopy more than 30 years ago that 
mitochondrial SQR stabilizes a ubi-semiquinone radical (94). Photoaffinity labeling 
with quinone analogs also identified potential amino acid residues in bovine 
mitochondrial SQR involved in side-chain interactions with the quinone (62, 103). 
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The crystal structure of E. coli SQR (Fig. 15) confirmed the general architecture of 
the quinone binding site in bacterial SQR (121).  
 
 
 
Figure 15. Q-binding sites in SQR and QFR in relation to the entire complex. (a) 
SQR Q-site. Ubiquinone carbon atoms are tan, with oxygen atoms are red. (b) QFR Q-site. 
Menaquinol carbon atoms are green, with oxygen atoms being red. In both panels, side-
chain carbon atoms are yellow, oxygen atoms are red, and nitrogen atoms are green. 
 
 
 
In E. coli SQR both the crystal structure (89) and kinetic data (67) are consistent 
with a single catalytic pocket termed the QP-site (for Q-proximal), where quinone 
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binds. The QP-site is located within 8 Å of the [3Fe:4S] cluster and 7 Å from the 
edge of the b-heme moiety, both distances well within the range for efficient electron 
transfer (86). Co- crystal structures are available for the E. coli SQR with ubiquinone 
and the Q-site inhibitor atpenin-A5 (36). The different binding positions for these 
molecules suggest that ubiquinone and ubi-semiquinone (the one-electron 
intermediate) bind in the SQR Q-site in two distinct positions during the catalytic 
cycle, consistent with other quinone binding sites, suggesting a general plasticity for  
 
 
Figure 16. Inhibitors bound to Q-sites in QFR and SQR. (a) The inhibitor atpenin-A5 
(carbon atoms are green) in the SQR Q-site and contacts. Carbon atoms of atpenin-A5 are 
green, with oxygen atoms in red and nitrogen atoms in blue. Side-chain carbon atoms are 
yellow; oxygen atoms are red, and nitrogen atoms are blue. Careful inspection of the 
atpenin-A5 binding site and the ubiquinone binding site (Fig. 15) shows a different binding 
position for these two species. (b) The QFR Q-site inhibitor 2-heptyl-4-hydroxy quinoline N-
oxide (HQNO; carbon atoms are magenta) with contacts. HQNO carbon atoms are 
magenta, with oxygen atoms being red and nitrogen atoms being blue. Comparison with Fig. 
15 shows that the position of this inhibitor is similar to that of the menaquinol. HQNO is 
proposed to act as a menasemiquinone analog. Side-chain carbon atoms are yellow, 
oxygen atoms are red, and nitrogen atoms are blue. 
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quinone binding sites. This phenomenon has previously been observed in the 
photosynthetic reaction center (19) and is proposed as a mechanism to protect the 
ubi-semiquinone radical intermediate from interaction with solvent. The co-structure 
of SQR with ubiquinone (121) reveals a single hydrogen bond between the 
ubiquinone O1 atom and the side chain hydroxyl of Tyr-D83 (Fig. 15). The 
costructure with the Q-site inhibitor atpenin-A5 (36) reveals that a deeper binding 
pocket for quinone is available (Fig. 16), which would prevent the premature 
disassociation of a highly reactive, partially reduced semiquinone. In the second 
binding position, additional hydrogen bonds to Ser-C27 and His-B207 bring 
ubiquinone into close proximity to a putative proton shuttle pathway (Fig. 17). This 
putative pathway would provide a mechanism for protons to enter the binding pocket 
in the membrane-spanning region.  
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Figure 17. SQR proton shuttle to ubiquinone binding site. (a) The SQR structure. (b) 
A close-up of the proton shuttle and ubiquinone binding site. The integral membrane 
subunits are represented with surface models and are purple (sdhD, SQR; frdD, QFR) and 
green (sdhD, SQR; frdD, QFR). The proton shuttle comprises ordered water molecules and 
residues Lys-B208, Lys-B230, Arg-C31, Asp-C95, Glu-C101, and Asp-D82. Water 
molecules are shown as red spheres. Side-chain carbons are yellow, oxygen atoms are red, 
and nitrogen atoms are blue. Ubiquinone is tan, and its oxygen atoms are red. Dashes 
represent the proposed pathway for the proton shuttle.  
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Cyt b556 
The crystal structure of SQR (121) includes a b-type heme (52) that uses His-C84 
and His-D71 as the Fe- ligands, confirming what was expected from spectroscopic 
studies (23, 70, 90). The position of heme b556 with respect to the electron transfer 
pathway was a surprise since the heme is off-pathway (Fig. 7) for electron transfer 
between the [3Fe:4S] cluster and ubiquinone. As electrons are delivered to the Q-
site from the [3Fe:4S] cluster, the structure raises the possibility that the first 
electron can reduce either the heme directly or the quinone. It is ~11 Å from the 
[3Fe:4S] cluster to the edge of the heme, whereas it is only ~7 Å from the Fe:S 
cluster to the quinone (121). Subsequently, EPR studies indicate that an intact 
quinone binding site is necessary for reduction of the heme (111). Although the 
logical conclusion from these studies is that the quinone is reduced before the 
heme, pulse radiolysis investigation of isolated E. coli SQR suggests that there can 
be a very rapid equilibration of the electron between the heme and the quinone so 
that first electron could be delivered to either redox center (4). Further study is 
clearly needed to clarify the role order of delivery of electrons to the b-heme.  
 The overall role of the heme in SQR is also controversial. One role for the 
heme is structural, as it has been shown that assembly of the SQR holoenzyme is 
perturbed in E. coli heme-deficient mutants (82). Another proposal is that the heme 
may act as an “electron sink” during reduction of the enzyme. This additional 
cofactor would prevent electrons from accumulating on the FAD when ubiquinone is 
not immediately available by diverting electrons away from the iron-sulfur clusters 
(121). Since single-electron-reduced FAD is highly reactive, an additional cofactor in 
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the membrane-spanning region would prevent back-reactions in vivo (i.e., fumarate 
reduction) and, more importantly, would prevent inappropriate reactions such as the 
partial reduction of O2 to form harmful reactive oxygen species (ROS) during aerobic 
respiration. The redox potentials of the cofactors in SQR would tend to pull electrons 
away from the flavin site, which is in direct opposition to what is the case for E. coli 
QFR where the cofactors are tuned so electrons are transferred toward the FAD 
(Fig. 7). This proposal is consistent with the known tendency of QFR to form ROS in 
vitro when oxygen is available from the flavin binding site, while SQR does not (38, 
74). These interesting findings suggest one reason that organisms have evolved 
both a SQR and a QFR. As pointed out by Imlay (38), as E. coli transits from an  
 
Menaquinol binding in QFR 
 The structure of QFR revealed electron density attributed to menaquinol in two 
positions: a proximal QP-position located in proximity to the [3Fe:4S] cluster of the 
frdB iron-sulfur protein subunit and a distal QD-position located on the opposite side 
of the membrane (Fig. 14) (44). The QP- and QD-sites are separated by ~25 Å, a 
distance too far for physiological electron transfer (86), in part explaining why QFR 
cannot itself support formation of a proton gradient. While the relevance of QD 
continues to be investigated, it is clear that menaquinol binding the QP-site is the 
immediate electron donor to the [3Fe:4S] cluster (32, 68, 106). Note also that a 
recent X-ray structure of porcine SQR also revealed two binding sites for the 
quinone site inhibitor 2-thenoyltrifluoroacetone (TTFA), and these sites were 
spatially separated across the membrane in a manner similar to what was seen in 
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QFR (106). There is no evidence that this distal quinone binding site has any 
functional significance in the mammalian SQR, and the hydrophobic TTFA inhibitor 
was crystallized with the enzyme at a concentration some two orders of magnitude 
higher than necessary for inhibition of the enzyme. It is also relevant that the di-
heme members of the SQR and QFR family of enzymes (32, 57, 59, 60, 72) have a 
functional quinone catalytic site on the distal side of the membrane. Thus, it should 
be considered that the QD-site might be an evolutionarily conserved hydrophobic 
pocket that is functionally active in the di-heme-containing enzymes but 
nonfunctional in the single heme and/or no-heme members of the SQR/QFR family.  
 Unlike SQR, where quinone analogs adopt somewhat different conformations 
as compared to ubiquinone, comparisons of the costructure of QFR and menaquinol 
with the costructure of QFR and the semiquinone analog 2-N-heptyl-4- 
hydroxyquinoline N-oxide (HQNO) (45) reveal that both menaquinol and the 
semiquinone analog effectively bind to the same site (Fig. 16). Several residues in 
the membrane-spanning subunits stabilize menaquinol binding at this position, 
including Trp-D14, Arg-C28, and Glu-C29 (Fig. 15) (44). Glu-C29 had previously 
been identified in random mutagenesis studies as being important for quinol binding 
(118). EPR analysis of the Glu-C29 → Leu mutation showed an alteration in the 
stability of the semiquinone radical by increasing the lifetime by four orders of 
magnitude (33). Glu- C29 may play an important catalytic role in protonation 
reactions and by destabilizing the semiquinol radical to prevent possible side 
reactions between it and oxygen.  
 An unusual aspect of the Q-site in QFR is the formation of a hydrogen-bonding 
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interaction from the Lys-B228 Nζ atom to the menaquinol O1 atom (Fig. 15) (45). 
Lys-B228 lies on an amphipathic helix that rests on the membrane, and the side 
chain is inserted down into the membrane bilayer. The formation of a hydrogen-
bonding interaction with menaquinol would neutralize the positive charge of this side 
chain and additionally suggests that this side chain is a  
possible proton donor (45). Even a conservative mutation to arginine abolishes both 
menaquinol oxidation and ubiquinone reduction.  
 
Evolution and similarity of SQR and QFR 
 As is described above, SQR and QFR share sequence similarity in the soluble 
domain, which suggests that they evolved from a gene duplication event. The 
strongest sequence similarity (58%) is observed in the flavoprotein subunit (A chain), 
which contains the active site for succinate-fumarate interconversion. The 
flavoprotein subunit also exhibits significant sequence and structural similarity to 
soluble fumarate reductases, as well as to L-aspartate oxidase in E. coli. These 
soluble counterparts lack a covalent bond to FAD and consequently lack succinate-
oxidizing ability (8, 79, 81, 109). This suggests that fumarate reduction came about 
first, with the ability to oxidize succinate occurring later with the formation of a 
covalent bond to FAD. Sequence comparisons between mitochondrial SQR and 
eubacterial homologs predict that those lineages have an ancient common origin in 
α-proteobacteria (11, 101).  
 Evidence for an ancient evolutionary origin of complex II enzymes comes from 
sequence relationships between iron- sulfur protein subunits (subunit B) of different 
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species (14). The iron-sulfur protein subunit is related in sequence to  
ferredoxins (Fig. 12), evolutionarily ancient redox-active proteins present in 
prokaryotes, in mitochondria and chloroplasts of eukaryotes, and in archaea. This 
suggests that they may have been present in the last universal common ancestor 
(LUCA) as part of a diverse array of respiratory processes. The iron-sulfur protein 
subunit originally may have been a separate soluble protein that transferred 
electrons between divergent reductases and membrane-bound four-helix bundle 
cytochromes. Over time, the iron-sulfur protein developed affinity for the flavoprotein 
subunit, followed by the membrane-spanning subunits, leading to the current subunit 
arrangement. Sequence and cofactor differences in the integral membrane subunits 
(subunits C and D) place SQR and QFR into separate subclasses (32), and here 
the enzymes differ substantially. E. coli SQR contains two transmembrane 
polypeptide chains bound to a single heme. In contrast, E. coli QFR contains two 
transmembrane subunits but lacks heme (32, 34). Through evolution, the iron-sulfur 
protein may have bound various membrane subunits, explaining the current diversity 
of membrane subunits found in homologs of SQR and QFR. 
 
Unanswered questions 
 One unanswered question revolves around whether small- and large-scale 
protein movements are required for succinate- fumarate interconversion. Domain 
rearrangements around the flavin cofactor may provide some catalytic control in the 
flavoprotein subunit. The flavoprotein subunits of SQR and QFR, along with soluble 
fumarate reductases, contain several conserved residues near the active site that 
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do not directly interact with the substrate. Furthermore, the conformation of two 
domains enclosing the active site is altered in many of the structures, which may be 
relevant to fumarate/succinate interconversion by coercing the molecules into a 
transition state and may also prevent access of water or oxygen to the active site 
during the formation of the transition state. The existence and importance of domain 
movements have been called into question since the introduction of a disulfide bond 
between domains, which theoretically restricts interdomain motions, does not 
completely abolish enzyme activity in soluble fumarate reductases (93). 
Furthermore, little evidence exists for how FAD is reprotonated during the active 
cycle or how the structure of FAD changes between oxidation and reduction.  
 Quinone chemistry in SQR and QFR is also an area of active interest. No well-
established mechanism exists for quinone reduction in SQR or quinol oxidation in 
QFR. The role of the heme in electron transfer reactions in SQR and other complex 
II homologs remains to be established as well. Furthermore, QFR is a much more 
potent producer of the superoxide than is SQR, yet differences in how these 
enzymes produce ROS (and under what conditions) remain unknown. Higher SQR 
cofactor potentials and the presence of a heme may shift electrons away from FAD, 
the known site of ROS production in QFR.  
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CHAPTER II 
 
 
A THREONINE ON THE ACTIVE SITE LOOP CONTROLS TRANSITION 
STATE FORMATION IN ESCHERICHIA COLI RESPIRATORY COMPLEX II1 
 
Abstract 
  In Escherichia coli, the complex II superfamily members suc- 
cinate:ubiquinone oxidoreductase (SQR) and quinol:fumarate reductase (QFR) 
participate in aerobic and anaerobic respiration, respectively. Complex II enzymes 
catalyze succinate and fumarate interconversion at the interface of two domains of 
the soluble flavoprotein subunit, the FAD binding domain and the capping domain. 
An 11-amino acid loop in the capping domain (Thr-A234 to Thr-A244 in 
quinol:fumarate reductase) begins at the interdomain hinge and covers the active 
site. Amino acids of this loop interact with both the substrate and a proton shuttle, 
potentially coordinating substrate binding and the proton shut- tle protonation state. 
To assess the loop’s role in catalysis, two threonine residues were mutated to 
alanine: QFR Thr-A244 (act-T; Thr-A254 in SQR), which hydrogen-bonds to the 
sub- strate at the active site, and QFR Thr-A234 (hinge-T; Thr-A244 in SQR), which 
is located at the hinge and hydrogen-bonds the proton shuttle. Both mutations 
impair catalysis and decrease substrate binding. The crystal structure of the hinge-T  
 
"This research was originally published in The Journal of Biological Chemistry 
Tomasiak, T.M., Maklashina, E., Cecchini, G., and Iverson, T.M. A threonine on the 
active site loop controls transition state formation in Escherichia coli respiratory 
complex II. J. Biol. Chem. 2008 283:15460-15468 . © the American Society for 
Biochemistry and Molecular Biology." 
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mutation reveals a reorientation between the FAD-binding and capping domains 
that accompanies proton shuttle alteration. Taken together, hydrogen bonding from 
act-T to substrate may coordinate with interdomain motions to twist the double bond 
of fumarate and introduce the strain important for attaining the transition state. 
 
Introduction 
  Complex II superfamily members catalyze two distinct capacity, 
complex II links the citric acid cycle to the electron transfer chain. The two reactions 
are coupled, since electrons that are the product of one reaction are transferred 
through the complex II enzyme to become the reactant of the second reaction. 
Homologues of complex II that preferentially oxidize succinate and reduce quinone 
participate in aerobic respiration are known as succinate:ubiquinone 
oxidoreductases (SQR; SdhCDAB). By contrast, those homologues that 
preferentially reduce fumarate and oxidize quinol are known as quinol:fumarate 
reductases (QFR; FrdABCD) and participate in bacterial anaerobic respiration with 
fumarate as the terminal electron acceptor.  
 Complex II enzymes contain four polypeptide chains, two of which, the 
flavoprotein (FrdA; SdhA) and the iron protein (FrdB; SdhB), are soluble subunits 
and two of which span the membrane (FrdCD; SdhCD) (2). Succinate and fumarate 
inter- conversion occurs in the flavoprotein, whereas quinol and qui- none 
interconversion occurs in the membrane-spanning region of the protein. In addition 
to the integral-membrane complex II homologues, there are known soluble 
homologues of the flavoprotein that only catalyze dicarboxylate oxidoreduction 
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without coupling this reaction to quinone chemistry within the membrane.  
Both the soluble and integral membrane homologues of complex II contain an 
FAD prosthetic group in the flavoprotein that performs hydride transfer during 
catalysis. In the membrane-bound forms of complex II, covalent binding of FAD 
raises its potential (Em7 =~-55 to -70 mV) and allows membrane-bound enzymes to 
proficiently oxidize succinate as well as reduce fumarate (3-6). In contrast, 
noncovalently bound FAD in the soluble bacterial homologues, such as 
flavocytochrome c3 (Fcc3) and l-aspartate oxidase, has a redox potential ~100 mV 
lower (~-150 mV) (7). As a result, these soluble homologues cannot proficiently 
oxidize succinate (8-11). 
X-ray structures from the complex II superfamily reveal that the active site for 
dicarboxylate oxidoreduction shares a common architecture with absolutely 
conserved catalytic residues (1, 2, 8-17). Like its eukaryotic and prokaryotic 
counterparts, the flavoprotein subunit of Escherichia coli SQR and QFR comprises 
two domains (i.e. an FAD-binding domain and a capping domain) with the active site 
at the domain interface. A short hinge region connects these two domains (Fig. 18A; 
residues 231-234 and 351-353 of the QFR flavoprotein subunit).  
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Fig. 18. Overview of active site architecture and the fumarate reduction reaction mechanism 
in complex II enzymes. A. The overall architecture of wild type E. coli QFR (PDBID 1KF6) is 
shown in relation to the membrane. The FrdA subunit (orange) is shown with the capping 
domain (grey) circled. The FrdB (blue), FrdC (green) and FrdD (yellow) subunits are shown 
as ribbons, with iron-sulfur clusters of the FrdB subunit shown as spheres. B. In QFR and 
soluble fumarate reductases, fumarate reduction is believed to occur in two distinct steps. 
The first is hydride transfer from reduced FAD and the second is proton transfer from Arg 
A287. Electron transfer and hydride transfer are displayed as red arrows and all proton 
transfer steps are shown with black arrows. Reprotonation of the Arg A287 side chain is 
achieved through a shuttle comprising Glu A245 and Arg A248. While re-reduction of the 
FAD requires two electrons that are transferred from iron-sulfur clusters in the iron protein 
subunit protein, the pathway for re-protonation of the FAD has not been elucidated. C. The 
QFR active site is located in the flavoprotein (FrdA) at the interface between the FAD 
binding domain (orange) and the capping domain (grey). The active site loop (cyan) 
contains both proton shuttling residues and substrate binding residues. Nitrogen atoms are 
colored blue, oxygen colored red, FAD carbons are yellow, and fumarate carbons are 
magenta. Side chain carbons are colored grey for Arg A245, Arg A248, and Arg A287; side 
chain carbons for act-T and hinge-T are colored cyan.  The location of fumarate in the active 
site is from an unpublished structure. Black arrows indicate the direction of proton transfer 
through the proton shuttle during fumarate reduction. 
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The FAD-binding and capping domains can assume any of a continuum of 
interdomain angles without distortion of the fold of either domain (2, 8-11, 18-23). 
These flavoprotein structures can be categorized into three groups, depending on 
interdomain orientation (19): domains “closed” over the active site (16, 18, 19, 22), 
domains rotated into an “open” position for solvent access into the active site (8, 9), 
and an “intermediate” position (10, 11, 20, 21, 23). Although all of the structures in 
the open state lack bound dicarboxylate at the active site (8, 9), there has also been 
a structure of a dicarboxylate-free active site in the closed position (16). In general, 
the majority of structures with ligand bound into the active site are in closed or 
intermediate positions that are nearly closed. The flavoproteins of both the Wolinella 
succinogenes QFR (20, 22) and the soluble Fcc3 flavoproteins (9, 10) have been 
observed with different domain angles in different crystal forms, suggesting that 
crystal packing forces can alter the interdomain angle and reflect the flexibility 
between these domains. The physiological significance of interdomain flexibility in 
the complex II superfamily is debated (24), and there is currently no known 
correlation between domain rotations and the catalysis. However, this type of 
interdomain movement has been suggested to control substrate access to the active 
site in a number of other flavoenzymes (25). 
 Intriguingly, the interdomain hinge between the FAD-binding and capping 
domains contains an absolutely conserved His-Pro-Thr motif that begins in an 11-
amino acid loop (Fig. 19A) containing residues important for catalysis in QFR and 
SQR (Fig. 18B). This active site loop begins at the hinge with a threonine (Thr-A234 
in the E. coli QFR, Thr-A244 in the E. coli SQR) denoted as the hinge-T. The loop 
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ends at a second threonine (Thr-A244 in E. coli QFR, Thr-A254 in the E. coli SQR) 
that forms a hydrogen-bonding interaction to the substrate in the active site and is 
denoted as act-T. The act-T hydrogen bond to substrate is particularly notable, since 
it may prime fumarate to accept hydride transfer from FAD, the first step in fumarate 
reduction by QFR. In solution, fumarate is a planar molecule constrained by a 
double bond (12); however, in complex II co-structures with fumarate, the O1 and 
O2 oxygen atoms are out of plane with the rest of the molecule (11, 20). The strain 
across the double bond of fumarate may facilitate hydride transfer from flavin N5 to 
fumarate C2 by stabilizing the transition state and lowering the transition state 
barrier (11, 12). 
The second step of fumarate reduction in QFR, protonation of the intermediate 
carbanion, may be influenced by hinge-T (QFR Thr-A234), located at the end of the 
interdomain hinge and the beginning of the active site loop. The hinge-T side chain 
Oγ forms a hydrogen-bonding interaction with the side chain  uanidine Nζ atom of 
Arg 248, which is a part of the proton shuttle that delivers a proton to the buried 
active site. This proton shuttle begins with Arg-A248, extends through Glu-A245, 
and ends with Arg-A287, which directly interacts with substrate (12, 26-29). In 
theory, the hydrogen-bonding interaction between the hinge-T Oγ and Arg-248 Nζ 
should lower the pKa of the arginine side chain and allow proton transfer at 
physiological pH values. 
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Materials and Methods 
 To further investigate the unique role of the active site loop in catalysis, the 
function of act-T (QFR Thr-A244; SQR Thr-A254) and hinge-T (QFR Thr-A234; SQR 
Thr-A244) was examined using alanine mutations in the E. coli QFR and SQR 
enzymes. Both mutants showed a loss of substrate binding and a loss of catalysis. 
Since the hinge-T does not interact directly with substrate, the basis for the loss of 
substrate binding in the hinge-T mutant QFR was evaluated using x-ray 
crystallography, which revealed that the absence of interpretable density for bound 
dicarboxylate resulted from a domain reorientation. The role of the hydrogen bonds 
provided by act-T and hinge-T are discussed for QFR and SQR, respectively. 
Bacterial Strains and Plasmids—E. coli strain DW35 (ΔfrdABCD, sdhC::kan), which 
was used as the host for expression of wild type and mutant forms of QFR and 
SQR, has been previously described (30). Plasmid pH3 (frdA+B+C+D+) was used 
for expression of wild type QFR (4), and plasmid pFAS (PFRDsdhC+D+A+B+) was 
used for expression of wild type SQR (31). 
 Mutagenesis—Mutation of individual amino acids was accomplished using 
the QuikChange (Stratagene, La Jolla, CA) site-directed mutagenesis kit. All 
mutations were verified by sequencing the HindIII-BstXI restriction fragment for 
SdhA mutations or the BstEII-ApaI fragment from FrdA. Mutagenized fragments 
were subcloned back into pFAS for SQR mutants or pH3 for QFR mutants. All 
cloning procedures were performed in accordance with methods previously 
described (4, 30, 31). 
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 Growth Conditions and Enzyme Purification—E. coli DW35 harboring the 
appropriate plasmid was grown under microaerophilic conditions in Terrific Broth 
medium as previously described (32). Isolation of membrane fractions (33) and 
subsequent purification of QFR and SQR enzymes were performed according to 
previously published methods (31, 34). Protein concentration was measured by the 
bicinchoninic acid method (Pierce) with bovine serum albumin as a standard. FAD 
and heme content were determined as previously described (32). 
Measurement of Enzyme Activity—To activate the enzymes, QFR and SQR 
were diluted to 5 mg of protein/ml in 30 mm BTP (BisTris-propane, pH 7.0), 0.1 mm 
EDTA, 0.05% Anapoe® C12E9 (Anatrace, Maumee, OH), 3 mm malonate and 
incubated for 20 min at 30 °C. For spectroscopic analysis, the enzymes were then 
concentrated with a Centriprep YM30 (Millipore) centrifugal filter device following the 
manufacturer’s instructions and then passed through a PD-10 gel filtration column to 
remove malonate. Activated enzyme was then stored on ice for the duration of the 
experiment. The standard assay medium at 30 °C contained 50 mm BTP, 0.1 mm 
EDTA, 0.006% C12E9 with the pH adjusted to intervals of 6.0-9.4 as appropriate. 
Potassium ferricyanide and phenazine ethosulfate/2,6-dichlorophenol indophenol 
were used as electron acceptors for reactions of succinate oxidation for QFR and 
SQR, respectively (35). Fumarate reduction was determined with reduced methyl 
viologen or by menaquinol oxidation, as described previously (36). Optical spectra 
were recorded with an Agilent 8453 diode array spectrophotometer 1 min after the 
addition of ligand to an isolated enzyme in 30 mm BTP, 0.1 mm EDTA, 0.01% 
Anapoe C12E9. 
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Crystallization of QFR FrdA T234A—QFR FrdA T234A crystals were grown 
from protein purified by previously described methods for wild type enzyme (37) 
using the hanging drop vapor diffusion method in 10% polyethylene glycol 5000 
monomethyl ether, 250 mm magnesium acetate, 100 mm citric acid, pH 5.8, and 0.1 
mm EDTA at 22 °C with drop sizes of 1 µl. QFR crystals formed in the orthorhombic 
space group P212121 with unit cell dimensions a = 96.9 Å, b = 135.5 Å, and c = 
266.0 Å with α = β = γ = 90° (Table 1). 
Data Collection, Processing, and Model Refinement—Data were collected at 
beamline 11-1 at the Stanford Synchrotron Radiation Laboratories on crystals 
cryoprotected with 30% ethylene glycol using a wavelength of 1 Å on an ADSC 
detector at 100 K. Data were processed using DENZO, SCALEPACK (38), and the 
CCP4 (39) suite of programs. Since crystals were isomorphous with crystals from 
known structures of wild type QFR, rigid body refinement was performed with CNS 
(40) to obtain initial model phases. Maps were calculated with CCP4 (39), CNS 
(40), and PHENIX (41). Iterative rounds of model rebuilding were performed in O 
(42) and COOT (43), whereas refinement was performed with CNS (40) and 
PHENIX (41) with loose non crystallographic symmetry restraints. 
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Table 2. Crystallographic data collection, processing, and refinement  
 
Wavelength (Å) 1.0 
Resolution (Å) 3.65  
 
Unit cell dimensions 
(Å) 
a = 96.9  
b =  135.5 
c = 266.0 
Space Group P212121 
Observations (#) 76015 
Unique (#) 32532 
I/σ 9.52(2.5) 
Completeness 80.3%  
Rsym1 8.4%(39%) 
Rwork2 24.68% 
Rfree3 29.54% 
RMSD4 Bond lengths 
(Å) 
0.019 
RMSD4 Bond angles 
(°) 
1.92 
1. Rsym = , where  and  are the ith and mean 
measurements of the intensity of reflection hkl.  
2. Rcryst = , where   and  are the observed and 
calculated structure factors for the reflection hkl and k is a weighting factor. 
3. Rfree = , where  and  are the observed and 
calculated structure factors for the reflection hkl and k is a weighing factor. T is the 
test set of reflections. 
4. Root mean square deviation 
 
 
Model building with omit maps was used to minimize map bias. Ab initio 
protein folding was performed with RAPPER (44). Final R-factors for the structures 
were Rcryst = 26.05% and Rfree = 29.57% with reasonable geometry. Figures were 
created in the program PyMOL (45). The Dyndom server (39) was used to 
calculate the angle of domain motions between wild type QFR and hinge-T QFR. 
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Results 
In this study, two conserved threonine residues have been mutated to alanine 
in QFR and SQR. The first of these, act-T (Thr-A244 in QFR; Thr-A254 in SQR), 
hydrogen-bonds to dicarboxylate substrates bound at the active site (10, 16, 18, 
21, 23). The second conserved threonine residue studied, hinge-T (Thr-A234 in 
QFR; Thr-A244 in SQR) hydrogen-bonds to Arg-A248 in the proton shuttle and is 
at the hinge region connecting the capping and FAD domains. 
Active Site Threonine Mutants—Wild type SQR oxidizes succinate with a high 
kcat of 110 s-1 (36); however, the SQR act-T mutant was incapable of succinate 
oxidation in the pH range of 6.0-9.0 tested. Moreover, heme b reduction was not 
observed upon prolonged incubation of the SQR act-T mutant with succinate, 
although wild type SQR heme b would be fully reduced under such conditions 
(data not shown). Similar to the SQR act-T mutant, the QFR act-T mutant (Thr-
A244 → Ala) was unable to oxidize succinate. Fumarate reductase activity in the 
QFR act-T mutant fell by more than 800-fold compared with wild type (Table 2). 
The residual activity depended upon fumarate concentration, with the Kfumm being 
increased by 40-fold (Table 2). Thus, the QFR act-T mutation affected both kcat 
and Km. 
The act-T substitution resulted in dramatic changes in the ligand-induced 
optical properties of act-T-QFR and act-T-SQR (Fig. 19). The amplitude of the 
spectral peaks at 400 and 500 nm are reduced 3-4-fold in the mutant enzymes, 
and there is a loss of the characteristic charge transfer band in the presence of 
OAA (Fig. 19).  
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Figure 19. Dicarboxylate induced optical changes in SQR and QFR enzymes (pH 7.0, 
25ºC). Difference spectra represent the effect of malonate (green), fumarate (blue), and 
OAA (magenta) on the spectrum of fully oxidized enzymes. Dicarboxylates were used at 
saturating concentrations for optical spectra.  For the wild type SQR and QFR the 
concentrations of ligands were 0.1 mM OAA, 1 mM malonate, 5 mM fumarate. For the 
SQR act-T and QFR act-T enzymes, the concentrations were 2 mM OAA, 10 mM 
malonate, 10 mM fumarate.  The protein concentration in all cases was normalized to 4.9 
µM for spectral analysis.  Shown in the figure are representative spectra of 4 independent 
experiments. 
 
These results are consistent with the observation that altered substrate 
binding prevents formation of the charge transfer complex and that both the QFR 
act-T and SQR act-T mutant enzymes are compromised in substrate binding 
(Table 3). This altered binding would preclude efficient catalysis. 
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Table 3.   Kinetic parameters of wild type and mutant QFR. 
 
 Fumarate reduction          Succinate oxidation 
 kcat (s-1) Kmfum (mM) kcat (s-1) Kmsucc(mM) KiOAA(µM) 
WT-QFR 340 0.02 30 0.55 0.3 
AcT-QFR 0.4 0.8 <0.03 nd nd 
HingeT-QFR 26 0.6 1.3 
 
2.7 
 
40 
All assays were done at 30 0C.  Fumarate reduction with methyl viologen  
(pH 7.0) and succinate oxidation with potassium ferricyanide (pH 8.0)  
were performed as described in “Experimental Procedures”. 
Nd, not determined 
 
 
Hinge-threonine Mutants—The next region targeted for mutagenesis was the 
conserved Thr in the His-Pro-Thr (HPT) sequence of QFR and SQR, since this 
hinge-T interacts with the proton-shuttling residue Arg-A248. The QFR hinge-T 
mutant showed expression levels similar to those of wild type QFR; however, the 
SQR hinge-T mutant was expressed at 5-7-fold lower levels than wild type (data 
not shown). The SQR hinge-T mutant lost succinate-ubiquinone reductase activity 
and heme b activity. Attempts to purify the SQR hinge-T mutant enzyme resulted in 
proteolysis, which was probably due to impaired stability and/or assembly of the 
mutant enzyme. 
In contrast, the QFR hinge-T mutant was amenable to enzymatic and 
structural analyses over a wide pH range. The hinge-T substitution significantly 
affected dicarboxylate binding at the active site (Table 2). The Km values for 
fumarate and succinate significantly increased, and the Ki for OAA increased by 
more than 100-fold (Table 2). Typical for complex II enzymes, the pH profile of kcat 
demonstrates a mirror-like profile, where succinate oxidation increases and 
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fumarate reduction decreases at high pH values (49). The QFR hinge-T mutation 
shifted the succinate oxidation pKa shift from 7.4 for wild type QFR to 8.7 in the 
mutant (Fig. 3). In the mutant, the fumarate reductase reaction is pH-independent 
over the pH range 6.0-8.5, consistent with the increase in apparent pKa to over pH 
8.5 (Fig. 20). Although overall catalytic activity is impaired in the QFR hinge-T 
mutant, the residual succinate oxidase activity at pH 9.0 is about 10% of wild type, 
and the fumarate reductase activity at pH 8.0 is also 10% of wild type QFR. 
 
 
Figure 20. pH dependence of succinate oxidase and fumarate reductase reactions 
catalyzed by wild type and hinge-T QFR enzymes (30ºC). Enzymatic activities of wild type 
QFR (open circles) and hinge-T (FrdA T234A; filled circles) were performed as described 
in “Experimental procedures” 
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In agreement with the kinetic data, ligand induced optical changes in the QFR 
hinge-T enzyme (Fig. 21). At pH 7.0, all three dicarboxylates examined induced 
similar spectral changes, and OAA clearly showed two spectral features. One was 
a peak at 500 nm characteristic of the other dicarboxylates. The second change 
was a significantly reduced charge transfer band (500-700 nm) compared with wild 
type QFR (Fig. 19), consistent with a change of relative orientation of the OAA and 
flavin in the mutant at pH 7.0 (48). At pH 9.0, where the hinge-T mutant 
demonstrated 10-fold higher activity than at pH 7.0, the increased absorbance of 
the charge transfer band closely resembled that seen for wild type QFR. The OAA-
induced optical changes for wild type QFR did not significantly differ between pH 
7.0 and 9.0 (Fig. 21). 
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 Figure 21.  Ligand induced optical changes of hinge-T QFR enzyme (25ºC).  A and 
B. Difference spectra show the effect of malonate (green, 10 mM) fumarate (blue, 10mM), 
and OAA (magenta, 2 mM) on the spectrum of fully oxidized FrdA T234A enzymes at pH 7.0 
(A) and 9.0 (B).  The concentrations of ligands were 10 mM malonate, 10 mM fumarate, and 
2 mM OAA. C. OAA induced spectral changes of wild type QFR at pH 7.0 (black) and 9.0 
(magenta).  Protein concentration of wild type and hinge-T QFR was 4.9 µM. 
 
 
Structural Characterization of the QFR Hinge-T Mutant—To provide a 
structural framework for how the hinge-T substitution affected substrate binding 
and enzyme activity, the structure was determined to 3.65 Å resolution using x-ray 
crystallography. Previous E. coli QFR structures show clear electron density for the 
weak inhibitor citrate bound at the active site, due to citrate in the crystallization 
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conditions (23, 50). The QFR hinge-T mutation caused a dramatically decreased 
affinity for dicarboxylate inhibitors (Table 3), and despite the presence of 100 mm 
citrate in the crystallization reaction, the structure of the mutant enzyme showed no 
clear electron density in the active site. 
Loss of substrate binding in the hinge-T mutant may be explained upon 
examination of the structure. In homologue structures where the capping domain 
and FAD domain are in a closed conformation (21, 23, 50), a minimum of one-third 
of the hydrogen bonds to substrate are provided by residues of the capping 
domain. In the QFR hinge-T structure, the capping domain rotated by 5.3°, opening 
a pathway to the active site (Fig. 22). The new rotated capping domain position 
resembles the maximally open conformation observed in the Shewanella Fcc3 
enzyme (9). This rotation moves the capping domain side chains into positions 
where they no longer hydrogen-bond to substrate or inhibitors. Consistent with this, 
all structures to date with an open position of the capping domain lack bound 
substrate at the active site. 
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Figure 22. Comparison of the position of the capping domain in wild type and hinge-T 
(FrdA T234A) QFR. The hinge-T QFR capping domain (green) is superimposed onto the 
flavoprotein of wild type QFR capping domain (grey). Green dashes connect the main 
chain of the hinge-T mutant in regions where the crystallographic electron density does not 
allow the main chain to be resolved unambiguously.  Side chain carbons are colored grey 
in wild-type QFR and are colored green in the hinge-T mutant. FAD carbons are colored 
yellow, nitrogen atoms are colored blue, oxygen colored red. A. In the hinge-T mutant, the 
structure of the FAD-binding domain (orange) is not significantly altered and can be 
superimposed with a RMS deviation of 0.3 Å.  However the capping domain has rotated 
5.3º with respect to the wildtype enzyme (PDBID 1KF6). The direction of the capping 
domain rotation and the proposed substrate path are denoted with black arrows. 
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Particularly important to catalytic activity are Arg-A287, the proton donor 
during reduction, and Thr-A244, which is critical for transition state formation. In the 
majority of crystal structures of complex II homologs, the  uanidine group of the 
residue equivalent to Arg-A287 is poised for proton transfer to substrate, since it 
forms a hydrogen bond to the bound dicarboxylate (10, 11, 19, 20, 22). In the 
hinge-T mutant, the movement of the capping domain into the open position shifted 
the Cα atom of Arg A287 5.5 Å from the active site and moved the Nζ atom of the 
side chain to a distance too far for proton transfer. The act-T side chain was also 
located on the capping domain. In the hinge-T mutant, the domain rotation moved 
the Cα atom of act-T by 1.5 Å and shifted the side chain away from the 
dicarboxylate binding site. The repositioning of both Arg-A287 and act-T may 
contribute to the observed decrease in the reaction rate in the hinge-T mutant. 
In the hinge-T mutant, the rotation of the capping domain into the open 
conformation was associated with decreased electron density quality compared 
with other regions of the mutant QFR. This was shown by an increase in 
crystallographic temperature factors. In the structure, the average temperature 
factor was 72 Å2 in the FAD-binding domain main chain as compared with 168 Å2 
in the capping domain main chain. A similar temperature factor increase is 
observed in the Shewanella Fcc3 open conformation structure (Protein Data Bank 
code 1QO8) (9). The electron density maps for the hinge-T mutation lacked 
appreciable density for many of the side chains. Nevertheless, it is clear that the 
domain rotation observed in the hinge-T mutation results in alterations of the  
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Figure 23. Comparison of the position of the capping domain in wild type and hinge-
T (FrdA T234A) QFR. The hinge-T QFR capping domain (green) is superimposed 
onto the flavoprotein of wild type QFR capping domain (grey). Green dashes 
connect the main chain of the hinge-T mutant in regions where the crystallographic 
electron density does not allow the main chain to be resolved unambiguously.  Side 
chain carbons are colored grey in wild-type QFR and are colored green in the hinge-
T mutant. FAD carbons are colored yellow, nitrogen atoms are colored blue, oxygen 
colored red. A. In the hinge-T mutant, the structure of the FAD-binding domain 
(orange) is not significantly altered and can be superimposed with a RMS deviation 
of 0.3 Å.  However the capping domain has rotated 5.3º with respect to the wildtype 
enzyme (PDBID 1KF6). The direction of the capping domain rotation and the 
proposed substrate path are denoted with black arrows. The altered position of the 
capping domain shifts the proton shuttling residues in the hinge-T mutant. Black 
arrows indicate the direction of local structural changes.  
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Hydrogen bond network of Arg-A287 and Arg-A248 in the proton shuttle, which may 
alter the pKa values of each side chain. In addition to the 5.5-Å shift of Arg-A287, the 
Cα atom of Arg-A248 shifted 2.1 Å away from the active site (Fig. 23). As described 
above, the hinge-T mutant had an altered pH profile as compared with wild type. The 
hinge-T Oγ-Arg-A248 Nζ hydrogen bond probably serves to modulate the pKa of 
Arg-A248 so that loss of the hydrogen bond from the Oγ of Thr-A234 to the 
 uanidine group of Arg-A248 may raise the pKa of the Arg-A248 side chain. 
Crystallographic electron density does not unambiguously reveal the Arg-A248 side 
chain position, which is most likely disordered and solvent-exposed. 
 
 
Discussion 
The E. coli complex II homologs QFR and SQR contain covalently bound FAD 
and thus are able to reversibly oxidize succinate or reduce fumarate (49). This 
makes them useful models for study of bidirectional catalysis in complex II 
enzymes (1, 12, 49). An active site loop identified between act-T (QFR Thr-A244; 
SQR Thr-A254) and hinge-T (QFR Thr-A234; SQR Thr-A244) was tested for its 
importance in catalysis of the reaction in both directions for two reasons; first, it 
provides numerous hydrogen bonds to substrate, and second, it provides a key 
stabilizing interaction with the proton shuttle. In this study, the role of the two 
conserved threonine residues in this loop was investigated. 
The Act-T Hydrogen Bond May Stabilize the Transition State—Structures of 
Fcc3 fumarate reductases and the W. succinogenes QFR co-crystallized with 
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fumarate show a twisted conformation of the C1 carboxylate in the species bound 
at the active site. Fumarate twisting may strain the double bond and decrease the 
free energy barrier for attaining the transition state (11, 12, 21). Elimination of the 
act-T side chain, which hydrogen-bonds to the carbonyl where fumarate is twisted, 
dramatically impairs catalysis of both the E. coli SQR and QFR enzymes (Table 2). 
The altered binding of dicarboxylate ligands in the act-T mutant is seen with the 
absence of CT absorbance upon OAA binding and significantly decreased spectral 
changes upon fumarate or malonate binding (Fig. 19). This suggests that the 
removal of the act-T Oγ hydrogen bond affects both substrate binding and 
transition state stabilization. In contrast, substitutions of other active site residues 
equivalent to E. coli FrdA His-232 and His-354 were mainly shown to affect 
substrate binding (12, 26, 51). 
Furthermore, in the Fcc3 enzyme, x-ray crystallography of a mutant enzyme 
equivalent to E. coli QFR FrdA H232A only showed subtle changes in the position 
of fumarate; however, the C1 carboxyl group is found in the same twisted 
conformation as in wild type enzyme (26), indicating that this histidine does not 
participate in transition state formation. The substitution of the active site threonine 
(FrdA Thr-244/SdhA Thr-254) to alanine caused a much more dramatic effect on 
complex II enzyme activity compared with the single substitutions of the two 
histidine residues found at the active site in the soluble Fcc3 enzyme (26). The 
results presented here are consistent with act-T being essential for positioning the 
C1 carboxyl of fumarate and efficient catalysis in the complex II family of enzymes. 
The Hinge-T Mutant May Trap the Proton Shuttle in an Intermediate State—
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Hinge-T (Thr-A234 in QFR; Thr-A244 in SQR) in the conserved His-Pro-Thr of the 
capping domain hydrogen-bonds to the Arg-A248 side chain, part of the complex II 
proton shuttle. The effect of removing this hydrogen-bonding interaction was 
investigated. The hinge-T variant enzyme demonstrates altered pH dependence of 
the catalyzed reactions. This has several plausible explanations that are not 
mutually exclusive. First, the elimination of the hydrogen bond from Thr-A234 to 
Arg-A248 may alter the Arg-A248 side chain conformation so that it no longer can 
transfer protons to Glu-A245, thereby disrupting catalytic activity. Since electron 
density for the side chain of Arg-A248 could not be observed in the hinge-T mutant 
structure, the orientation of Arg-A248 in the hinge-T variant cannot be 
unambiguously established. A second explanation is that the loss of a hydrogen 
bond to Arg-A248 may shift the pKa of the proton shuttle. This may correlate with 
the increased succinate oxidase activity and stabilization of the OAA anionic 
transition state at high pH. In wild type QFR, the CT amplitude does not change at 
pH 7 or 9 and does not correlate with the pKa of the reaction (36, 49). This 
suggests that microscopic pKa values of amino acid residues involved in substrate 
activation are below pH 7, and the observed pKa of the reaction is influenced by 
other active site or proton shuttle residues. Increased stabilization of the CT 
species in the hinge-T mutant with increased pH may reflect either change in the 
pKa of the residues involved in substrate activation or conformational changes in 
the movable capping domain that effect ionization properties of the active site 
residues and/or substrate binding position. 
Proton Shuttle Regeneration May Trigger Domain Movements during 
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Catalysis—Unexpectedly, a dramatically decreased substrate affinity is observed in 
the hinge-T mutant enzyme. The x-ray structure of the hinge-T variant reveals a 
rearrangement between the FAD-binding and capping domains of the flavoprotein 
subunit that disrupts hydrogen bonding to substrate and prevents optimal substrate 
orientation for catalysis. Sequence and structural analysis support the possibility 
that the orientation between the capping domain and FAD-binding domain is not 
fixed. The capping domain contains a disproportionate number of glycine residues. 
Of the 120 residues in the capping domain, 19 are glycines, and of those, seven 
are within the first 20 residues of the capping domain. Glycines typically 
predominate where their added flexibility allows conformational rearrangements of 
proteins. 
The interdomain angles appear to be influenced by the presence of substrate 
at the active site. In the higher resolution Fcc3 structures (11), which allow for 
reliable identification of hydrogen bonds, only 11 interdomain hydrogen bonds 
between the FAD domain and the capping domain stabilize the closed state. Of 
these, six are between the polypeptide chains, and five are to substrate. 
Consequently, lack of bound substrate would probably destabilize a closed 
conformation. Similarly, the wild type E. coli QFR structure was determined in 
complex with citrate in an intermediate position of the FAD-binding and capping 
domains (50). In the intermediate structure, a decreased percentage of stabilizing 
hydrogen-bonding interactions are observed; only eight hydrogen bonds mediate 
this contact. In this case, it is the hydrogen bonds to the dicarboxylate that are 
exclusively lost, such that in the intermediate position of the capping domain, only 
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two through-substrate bonds remain. Furthermore, all open structures of 
flavoprotein homologues, including this new structure of the hinge-T mutant, lack 
crystallographic electron density corresponding to bound dicarboxylate at the 
active site. 
In previous structures, it was unclear how crystal contacts influenced domain 
opening. This hinge-T mutant has the same crystal packing as wild type and 
exhibits a domain rotation, indicating that the rotation is probably correlated to the 
enzymatic state and not an artifact of different crystallization conditions. The low 
number of stabilizing contacts, a high percentage of which are through substrate, 
suggests that the kinetic barrier between open and closed states is low and can be 
influenced by substrate binding. As a result, substrate binding or proton shuttle 
state could heavily influence the conformation. Flavoproteins in general may use 
such movements to control active site solvation as a means of optimizing catalysis 
and even determining the enzyme’s role as an oxidase, oxygenase, or 
dehydrogenase (25, 52). 
The possibility that domain reorientation accompanies catalysis and may 
correlate with the proton shuttle state stands in contrast to previous studies in a 
soluble QFR homolog (Fcc3) from Shewanella frigidimarina, which suggest a 
minimal role for capping domain mobility in fumarate catalysis (24). There, a 
disulfide bond was introduced between the capping domain and the rest of the 
flavoprotein to restrict capping domain movement. This disulfide bond reduced 
catalysis by 90%, and it was argued that this constituted an insignificant decrease 
in activity. One possible explanation for the difference in models from Fcc3 and the 
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QFR hinge-T mutant could be due to the nature of soluble fumarate reductases 
compared with membrane-bound complex II homologs. In all structures of the E. 
coli QFR determined to date, the electron density maps showed significantly better 
quality for integral membrane polypeptides than for the soluble domain.4 Thus, it is 
possible that membrane association may add stability to the entire protein and 
allow for conformational freedom in the soluble domain in E. coli QFR. 
Furthermore, other capping domain movements may compensate for the motion 
restriction imposed by the disulfide bond, allowing the substrate access to the 
active site. 
Act-T May Work in Concert with Domain Movements to Promote the 
Formation of the Transition State—Although there are several possibilities for the 
observed domain reorientations in the hinge-T mutant, the design of this variant to 
mimic a regenerating proton shuttle suggest that this movement accompanies 
catalysis. As seen in Fig. S1 (movie), a channel that forms in the ligand-free 
conformation allows substrate to access the active site. The open orientation of the 
two domains poises the act-T side chain to form essential hydrogen-bonding 
interactions that selectively pull the substrate into the active site. Subsequently, the 
bonds between act-T and substrate may induce active site closure by rotation of 
the capping domain to form further hydrogen bonding interactions with the 
substrate. Domain closure may force the interaction between act-T and substrate 
to twist the C1 carboxyl group and strain the double bond of fumarate while 
concomitantly orienting the proton shuttle Arg-A287 into an optimal position for 
catalysis. In this now solvent-protected active site, the dicarboxylate transition state 
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can accept hydride from FAD and a proton from Arg-A287. 
 
Conclusions 
The roles of two threonine residues on an active site loop were analyzed with the 
mutation to alanine. The act-T mutation shows the importance of a hydrogen bond to 
substrate that stabilizes the high energy intermediate states. Movement of the active 
site loop and the capping domain from open to closed states may serve to twist the 
substrate into a transition state for catalysis. Fluctuation between the open and 
closed states of the capping domain may protect the high energy intermediate from 
water in the active site while still permitting substrate binding in the open state. This 
may serve as an important mechanism to enhance on-pathway catalytic efficiency 
while minimizing the formation of off-pathway side products. 
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CHAPTER III 
 
GEOMETRIC RESTRAINT DRIVES ON- AND OFF- PATHWAY CATALYSIS BY 
THE ESCHERICHIA COLI MENAQUINOL:FUMARATE REDUCTASE 
 
Abstract 
Complex II superfamily members catalyze the kinetically difficult interconversion of 
succinate and fumarate. Due to the relative simplicity of complex II substrates and 
their similarity to other biologically abundant small molecules, substrate specificity 
presents a challenge in this system. In order to identify determinants for on-pathway 
catalysis, off-pathway catalysis, and enzyme inhibition, crystal structures of 
Escherichia coli menaquinol:fumarate reductase (QFR), a complex II superfamily 
member, were determined bound to the substrate, fumarate, and the inhibitors 
oxaloacetate, glutarate, and 3-nitropropionate. Optical difference spectroscopy and 
computational modeling support a model where QFR twists the dicarboxylate, 
activating it for catalysis. Orientation of the C2-C3 double bond of activated fumarate 
parallel to the C(4a)-N5 bond of FAD allows orbital overlap between the substrate 
and the cofactor, priming the substrate for nucleophilic attack.  Off-pathway  
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catalysis, such as the conversion of malate to oxaloacetate or the activation of the 
toxin 3-nitropropionate may occur when inhibitors bind with a similarly activated 
bond in the same position. Conversely, inhibitors that do not orient an activatable 
bond in this manner, such as glutarate and citrate, are excluded from catalysis and 
act as inhibitors of substrate binding. These results support a model where 
electronic interactions via geometric constraint and orbital steering underlie catalysis 
by QFR. 
 
Introduction 
Complex II superfamily enzymes provide a crucial link between oxidoreduction 
reactions in the membrane bilayer and in the soluble milieu (1). During aerobic 
respiration in E. coli, the complex II enzyme succinate:ubiquinone oxidoreductase 
(SQR) oxidizes succinate and reduces ubiquinone. In bacterial anaerobic respiration 
with fumarate as the terminal electron acceptor, the reaction proceeds in the 
opposite direction, and the complex II homolog menaquinol:fumarate oxidoreductase 
(QFR) oxidizes menaquinol and transfers the electrons to fumarate. Complex II 
superfamily members contain either three or four polypeptide chains (Fig. 24): two 
soluble subunits (the flavoprotein, FrdA, and the iron protein, FrdB in E. coli QFR) 
and either one or two integral membrane subunits (FrdC and FrdD in the E. coli 
QFR). 
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Figure. 24. Structure of the E. coli QFR and relevant ligands. A. Structure of the E. coli QFR 
heterotetramer with the flavoprotein subunit (FrdA) colored grey, iron-sulfur protein (FrdB) 
colored orange, and the transmembrane subunits colored blue (FrdC) and green (FrdD).  
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While there are significant differences in the integral membrane subunits across the 
family, complex II enzymes all share a high percentage of sequence identity in the 
soluble subunits, including the flavoprotein, where the kinetically challenging 
oxidoreduction of fumarate and succinate takes place (1). Numerous molecules 
including metabolic intermediates and ingested toxins structurally resemble 
succinate and fumarate. Some of these are excluded from the active site, while 
others act as inhibitors (Fig. 25). 
 
Figure. 25 B. Structures of the substrate, fumarate, the product, succinate, and molecules 
that interact with the dicarboxylate binding site and are discussed in this work.  
 
Several of these come from normal respiratory processes. For example, 
oxaloacetate is a Krebs cycle intermediate and acts as a tight, slow-binding inhibitor 
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of complex II, possibly as a regulatory mechanism (2,3). It has additionally been 
proposed that oxaloacetate can be formed through off-pathway catalysis by complex 
II when fumarate hydration to malate is followed by oxidation to oxaloacetate (3,4). 
Oxaloacetate binding to the complex II active site results in a charge transfer 
complex between the oxaloacetate carbonyl and the FAD hydride that can be 
monitored spectroscopically (4,5).  
Along with physiological regulation from metabolites, complex II activity may be 
affected by overproduction of dicarboxylates that result from dysfunction of cellular 
catabolic pathways. For example, mutation of glutaryl co-A decarboxylase can lead 
to elevated levels of the dicarboxylates glutarate and 3-hydroxy glutarate (Fig. 1B) 
and this has been associated with glutaric acidemia type I, which has symptoms that 
include cerebral swelling and motor defects (6). Respiratory chain deficiency 
correlates with glutaric acidemia type I, and complex II inhibition is observed in cell 
culture upon application of glutarate (7).  
Ingested toxins offer a third source of complex II inhibitors, often with severe 
health consequences. The fungus Arthrinium sphaerospermum produces the 
secondary metabolite 3-nitropropionate (3-NP) an irreversible complex II inhibitor 
(Fig. 1B)(8-10). When ingested, 3-NP can induce striatal brain lesions similar to 
those observed in patients with Huntington's disease, an autosomal dominant 
neurodegenerative disease characterized by dyskinesia, cognitive defects, and 
psychological pathologies (11).  In fact, 3-NP is commonly used to recapitulate a 
subset of the pathologies of Huntington's Disease in animal models (11). The 
mechanism of 3-NP inhibition of complex II is under debate. Previously, 3-NP has 
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been proposed to form a covalent adduct with either FAD (8), an active site cysteine 
residue (12), or a catalytic arginine near the dicarboxylate binding site (13). The 
formation of any of these adducts likely requires a single enzyme turnover, but has 
not been determined conclusively (12). 3-NP has also been proposed to act as a 
non-covalent inhibitor of complex II enzymes (14).  
To study the details of complex II catalysis and inhibition at the flavoprotein 
active site, the E. coli QFR was co-crystallized with the substrate, fumarate, and the 
inhibitors, oxaloacetate, glutarate, and 3-NP. Mass spectrometry and optical 
spectroscopy allowed unambiguous confirmation of the covalent 3-NP adduct and 
the proposal of a possible reaction mechanism. The implications for fumarate 
turnover and the mechanisms of inhibition are discussed. 
 
Materials and Methods 
QFR purification– E. coli QFR was produced in E. coli strain DW35 (ΔfrdABCD, 
sdhC:kan) containing the pH3 (frdA+B+C+D+) plasmid. Cells were grown under 
microaerophilic conditions in Terrific Broth medium as previously described (15). 
Membranes were isolated as described in (15) and were resuspended in a solution 
of 20 mM Tris, 0.1 mM EDTA (pH 7.4) and solubilized with C12E9 detergent 
(Anatrace, Maumee, OH) added to a final concentration of 2% (w/v). Purification of 
QFR was performed in the presence of 0.05% (w/v) C12E9 as described (15) using 
Q-sepharose anion exchange (GE Healthcare), POROS anion exchange (Applied 
Biosystems), and size exclusion chromatography on a superdex S-200 column (GE 
Healthcare).  
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Enzyme assays– In order to measure full succino-quinone reductase or succino-
oxidase activity of QFR, it is necessary to remove any tightly bound oxaloacetate, 
which co-purifies with the as-isolated enzyme (3).  To activate the enzyme, QFR was 
diluted to 5 mg of protein/ml in 30 mM Bis-Tris-Propane (BTP), pH 7.0, 0.1 mM 
EDTA, 0.05% C12E9, and 3 mM malonate and incubated for 20 min at 30o C.  The 
enzyme was then concentrated with a Centricon YM30 filtration apparatus and the 
concentrated protein was passed through a PD-10 gel-filtration column to remove 
malonate. Activated enzyme was then stored at 4o C until used.  The standard assay 
medium at 30° C contained 50 mM BTP, 0.1 mM EDTA, 0.006% C12E9, pH 8.0.  
Succino-oxidase activity of QFR was measured with the electron acceptor potassium 
ferricyanide as previously described (16). In order to determine apparent affinity 
constants for the dicarboxylates used in this study, inhibition of the ferricyanide 
reductase activity was determined as previously described (17).  
Optical difference spectra– Optical properties of all of the bound ligands were 
measured with an Agilent 8453 diode array UV/VIS spectrophotometer 1 min after 
addition to isolated enzyme in 30 mM BTP, 0.1 mM EDTA, 0.01% Anapoe C12E9. 
Optical spectra were recorded at 25 oC in 50 mM HEPES, 100 mM NaCl, 0.01% 
Thesit using 1.25 mg/ml of isolated and activated E. coli QFR. Upon addition of the 
ligand, a spectrum was recorded and the spectrum of oxidized enzyme subtracted.  
Each spectrum represents the addition of the different ligands at the concentration 
of, 5 mM fumarate, 50 µM oxaloacetate, 4 mM malonate 12 mM glutarate, 50 mM 
citrate, and 0.1 mM 3-NP which was added from an alkaline solution.  The spectra 
were recorded 10 min after the addition of the ligand. Inhibition of the enzyme by 3-
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NP was determined as described by adding a final concentration of 0.2 mM 3-NP 
from a pH 10.0 solution to activated QFR (pH 8.0) and measuring kinetic and optical 
properties at pH 8.0. 
Mass-spectrometry of 3-nitropropionate incubated QFR– QFR at (10 mg/mL) in 
20 mM glycine pH 10.0, 0.1 mM EDTA and 0.05% C12E9 was incubated with 1 mM 
3-NP for 1 hr on ice in a buffer consisting of 20 mM glycine pH 10.0, and 0.05% w/v 
C12E9 detergent and was incubated on ice for 1 hr.  The QFR subunits were 
separated on a NuPAGE SDS gel (Invitrogen). The 66 kDa FrdA subunit was 
manually excised and digested with trypsin for 2 hrs at 37°C.  The resulting peptide 
mixture was separated with a microcapillary HPLC system (Eksigent 1D plus with 
AS1 autosampler) using an 11 cm x 100 µm C18 reversed phase column (Jupiter 
C18, 5 µm, Phenomonex) packed directly into a nanospray emitter tip.  Using a 
nanospray source, this was interfaced with either a nominal mass resolution LTQ or 
high resolution LTQ-orbitrap (Thermo Fisher) mass spectrometer where data 
dependent tandem (MS/MS) and MSn spectra were collected throughout a 90 min 
separation.  These spectra were searched against an E. coli protein database 
considering potential amino acid mass differentials corresponding to 3-NP adducts 
using SEQUEST (Thermo Electron, (18)). Subsequent injections targeting potentially 
modified peptides were also performed; this included the targeting of normal and 
stable isotope labeled 3-NP adducts using the LTQ-orbitrap. Later, it was 
determined that adduct formation could occur at physiological pH. As a result, the 
analysis of 15N-labeled 3-NP adduct was performed with a modified pre-incubation 
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procedure where 10 mg/mL QFR was incubated with 1 mM 15N labeled 3-NP in a 
buffer consisting of 20 mM Tris pH 7.4, 0.1 mM EDTA, and 0.05% C12E9. 
     Synthesis of isotope labeled 3-NP derivatives– 3-Bromopropionic acid (250 mg, 
1.63 mmol), Na15NO2 (206 mg, 2.94 mmol, 98% 15N), phloroglucinol (227 mg, 1.80 
mmol), and DMF (3.3 mL) were added to a flame-dried round bottom flask. The 
reaction mixture was stirred at room temperature for 22 h, and then poured onto ice 
water and extracted with diethyl ether. The combined organic layers were dried over 
MgSO4, filtered, and concentrated. A portion of the residue was sublimed (80 °C, 1 
Torr) to yield 16 mg of the yellow crystalline product.  Label incorporation, sample 
purity, and confirmation of structure were determined by NMR: 1H NMR (400 MHz, 
CDCl3) δ 4.66 (td, J = 6.0, 2.4 Hz, 2H), 3.06 (td, J = 6.4, 4.0 Hz, 2H); 13C NMR (100 
MHz, CDCl3) ppm 174.3, 69.3, 30.6; 15N NMR (60 MHz, CDCl3) ppm 379.5.  
Crystallization of the E. coli QFR with ligands– All crystallizations of QFR used 
the hanging drop vapor diffusion method at 22 °C and crystallization conditions 
modified from those previously described (19). QFR was co-crystallized with 
fumarate in 12.5% polyethylene glycol (PEG) 8000, 85 mM MgCH3COO, 100 mM 
NaCitrate pH 5.8, 0.1% DTT, 0.1mM EDTA, and 5mM fumarate. QFR was co-
crystallized with oxaloacetate in 12% PEG 5000 monomethyl ether (MME), 125 mM 
MgCH3COO, 100 mM NaCitrate pH 5.8, 0.1% DTT, 0.1 mM EDTA, and 0.5 mM 
oxaloacetate. QFR was co-crystallized with glutarate in 14.5% PEG 8000, 125 mM 
MgCH3COO, 95 mM NaCitrate pH 5.8, 0.1% DTT, 0.1 mM EDTA, and 10 mM 
glutarate. For co-crystallization of QFR with 3-NP, prior to crystallization, QFR was 
incubated with a 3-fold molar excess of 3-NP on ice for 1 hr at pH 10.0. Crystals 
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were grown in 10% PEG 5000 MME, 250 mM MgCH3COO, 100 mM NaCitrate pH 
5.8, 0.1% DTT, and 0.1 mM EDTA. All crystals formed in the orthorhombic space 
group P212121 with unit cell dimensions and data collection statistics shown in Table 
1. 
 
 
TABLE 4. Crystallographic data collection and refinement statistics 
 
    + Fumarate +Glutarate +3-NP  +Oxaloacetate 
Wavelength   1.0 Å  1.03 Å  1.0 Å  1.2 Å 
Beamline   SSRL 9-2 SSRL 11-1 ESRF ID-13 SSRL 9-2 
Resolution   2.80 Å  3.05 Å  3.10 Å  3.35 Å 
Completeness    94.9% (95.6%) 95.0% (96.6%) 92.9% (78.2%)
 88.9% (73.9%) 
I/σ    23.4 (5.8) 10.7 (3.5) 16.8 (4.1) 10.0 (2.7) 
Rsyma    0.089 (.298) 0.099 (.296) 0.098 (0.256) 0.099 (0.237) 
Refinement statistics 
Rcrystb    0.249  0.248   0.255  0.220 
Rfree    0.272  0.284  0.279  0.261 
RMS deviation bonds (Å) 0.014  0.014  0.007  0.011 
RMS deviation angles (°) 1.854  1.888  1.651  1.868 
Values in parenthesis indicate statistics for the highest shell. 
aRsym = Σ |Ii - <I>|/ Σ Ii where I is intensity, “I” is the ith measurement, and <I> is the 
weighted mean of I. 
bRcryst = Σ ||Fobs| - |Fcalc||/ Σ Fobs. Rfree is the same as Rcryst for a set of data omitted from the 
refinement.  
 
 
 
 
Data collection and processing– Crystallographic data were collected at the 
beamlines listed in Table 1 at -173 °C after the addition of 30% ethylene glycol to the 
crystallization conditions as a cryoprotectant. Data were processed using DENZO, 
SCALEPACK (20), HKL2000 (21), and the CCP4 suite of programs (22). Since 
crystals were isomorphous with crystals from known structures of QFR, rigid body 
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refinement was performed with CNS (23) to determine initial phases. The starting 
model was QFR in complex with heptyl quinoline N-oxide (PDBID 1KF6, (24)) for the 
3-NP and glutarate co-structures, a QFR in complex with citrate  (PDBID 2B76; (17)) 
for the fumarate co-structure, and the finished glutarate co-structure for the 
oxaloacetate co-structure. Iterative rounds of model rebuilding were performed in O 
(25) and COOT (26). Omit maps, starting with segments of 50 amino acids in the 
initial stages of refinement and eventually progressing to 250 amino acid segments, 
were used extensively to minimize electron density map bias to the starting model. 
Refinement and map calculations were performed with Refmac5 (22,27), CNS, and 
Phenix with loose 2-fold non-crystallographic symmetry restraints used in the 
fumarate structure and translation-liberation-screw (TLS) refinement (28) in all the 
structures. TLS refinement parameters were determined with the TLSMD server 
(29). Figures 1A and 2 were created in the program PyMOL. 
Molecular modeling of dicarboxylate binding– QFR co-structures with fumarate, 
glutarate, oxaloacetate, and citrate were prepared for modeling with Maestro 
(Schrödinger LLC, (30)) by creating a file with only the flavoprotein subunit, the iron 
protein subunit, and covalently linked FAD. Protons were added to the QFR 
structure with Maestro, and the resultant structure was minimized using the 
molecular mechanics force field, OPLS_2005. Ligands were prepared using the 
Ligprep module by adding explicit hydrogen atoms. These ligands were then 
reinserted into the active site of the minimized protein. The Glide XP subroutine in 
Maestro was used for ligand docking and the free energy of binding was estimated 
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with the extended-precision scoring function (Glide XP)(30). During this phase of the 
calculation, flexibility of the ligand was allowed, while the protein was held rigid. 
Ligand binding and orientation were verified using omit maps and simulated 
annealing omit maps to minimize phase bias. Placement of multiple conformations of 
each ligand were attempted and were minimized using real space refinement in 
Coot. Docking of each ligand was tested using Glide to ensure that a physically 
reasonable binding orientation had been found (Fig. 26).  
 
Results 
QFR activity can be inhibited both in vivo and in vitro by dicarboxylates or 
carboxynitro molecules structurally similar to fumarate (Fig. 25). In this study, we 
investigate the determinants for binding and catalysis by identifying the interactions 
between QFR and the substrate fumarate, or the inhibitors oxaloacetate, glutarate, 
and 3-nitropropionate.   
Structural details of fumarate binding with the E. coli QFR– Co-crystallization of QFR 
with fumarate resulted in the appearance of clear electron density within the enzyme 
active site.  This density is consistent with an alignment of the C2-C3 double bond 
parallel to the C(4a)-N5 bond of the isoalloxazine ring of FAD (31). Notably, a 
torsioned conformation of fumarate is observed (Fig. 27), where the carboxylates are 
oriented 54° relative to one another, compared to the 0° orientation found in planar 
molecules. 
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Figure 26. Electron density of ligand binding to the active site. The active site of QFR is 
shown with nitrogen atoms colored blue, oxygen atoms colored red, carbons from the 
protein colored grey, carbons from the FAD colored yellow, and carbons from each bound 
ligand colored cyan. A. Active site of QFR co-crystallized with fumarate. B. Active site of 
QFR co-crystallized with oxaloacetate. C. Active site of QFR co-crystallized with 3-
nitropropionate. D. Active site of QFR co-crystallized with glutarate. 
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Figure 27. Fumarate binding to the active site. The active site of QFR is shown with 
nitrogen atoms colored blue, oxygen atoms colored red, carbons from the protein colored 
grey, carbons from the FAD colored yellow, and carbons from each bound ligand colored 
cyan. Relevant inter-atomic distances, including potential hydrogen bonds, are indicated 
along a dashed line. A. Active site of QFR co-crystallized with fumarate. 
 
Torsion of fumarate is predicted to have a significant electronic effect, with the C2 
carbon bearing the twisted carboxylate becoming a better hydride acceptor as 
 111 
electrons are better allowed to localize to the carbonyl (31,32). Hydride transfer thus 
presumably occurs between N5 of FAD and C2 of fumarate, and the distance 
between these atoms is 4 Å. Subsequent proton transfer is predicted to occur 
between the side chain of Arg-A287 and the C3 of fumarate. Of note, an ordered 
water molecule mediates the interaction between the C3 position of fumarate and 
the proton shuttle, Arg-A287.  Seven putative hydrogen-bonding contacts stabilize 
fumarate in this torsioned conformation (Fig. 28).  
The possibility of enzymatic turnover or photoreduction during data collection 
precludes positive identification of this dicarboxylate as fumarate with 
crystallography alone. To support the assignment of the ligand as fumarate (rather 
than citrate from the crystallization conditions, or the product succinate), optical 
difference spectra were collected. The binding of fumarate to QFR results in the 
appearance of peaks at 390 nm and 500 nm in the FAD absorption spectrum (Fig. 
30). The addition of QFR to the crystallization buffer induced optical changes that 
indicate replacement of oxaloacetate with citrate.  Upon addition of 5 mM fumarate, 
the concentration used during co-crystallization, a typical optical spectrum reflecting 
the replacement of citrate with fumarate was observed (data not shown).  
Structural details of QFR inhibition by oxaloacetate– The structure of QFR in 
complex with oxaloacetate shows that this dicarboxylate inhibitor binds to QFR with 
a position similar to that of fumarate (Fig. 28). 
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Figure 28. Oxaloacetate binding to the active site. The active site of QFR is shown with 
nitrogen atoms colored blue, oxygen atoms colored red, carbons from the protein colored 
grey, carbons from the FAD colored yellow, and carbons from each bound ligand colored 
cyan. Relevant inter-atomic distances, including potential hydrogen bonds, are indicated 
along a dashed line. A. Active site of QFR co-crystallized with fumarate. 
 
 
 
In this binding mode, the C2-C3 bond is parallel to C(4a)-N5 of the FAD 
isoalloxazine ring, similar to the orientation of the C2-C3 double bond of fumarate in 
the co-structure of fumarate with QFR. In addition, the oxaloacetate carbonyl is 
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positioned laterally such that C2=O carbonyl is nearly parallel with the adjacent N5-
C(5a) bond. This structural feature possibly underlies the charge-transfer interaction, 
which results in the formation of a broad peak in the optical spectrum centered at 
550 nm (Fig. 30). Interestingly, while the apparent affinity of oxaloacetate to QFR is 
much greater than that of fumarate, only three putative hydrogen bonds stabilize 
oxaloacetate in this binding position (Fig. 28). This suggests that the charge-transfer 
interaction has a major contribution to binding affinity. 
Structural basis of covalent inhibition by 3-NP– Differences in inhibition between 
SQR and QFR have mechanistic implications since each of these enzymes optimally 
catalyzes the reaction in one direction. As a result, we tested the effects of 3-NP 
addition on both wild-type QFR and the FrdA E49Q variant of QFR, which has 
previously been shown to have altered catalytic efficiency for fumarate reduction and 
succinate oxidation (17). Crystals of the FrdA E49Q variant of QFR in complex with 
3-NP exhibited superior diffraction as compared to crystals of wild-type QFR in 
complex with 3-NP. As a result, crystals of the mutant enzyme were used for all 
subsequent structural analyses.  
In the structure of 3-NP with the E49Q variant of QFR, electron density 
contiguous with Arg-A287 is evident, consistent with the formation of a covalent 
adduct between 3-NP and Arg-A287. This density is in the same location as the 
ordered solvent molecule observed in the co-structure between QFR and fumarate 
(Fig. 27). Proposed adducts from the literature were used as starting models to 
interpret the active site density, including 3-NP as a non-covalent inhibitor (14), 3-NP 
forming an adduct to Arg-A287 (13), 3-NP forming a covalent adduct to the FAD  
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Figure 29. 3-NP binding to the active site. The active site of QFR is shown with nitrogen 
atoms colored blue, oxygen atoms colored red, carbons from the protein colored grey, 
carbons from the FAD colored yellow, and carbons from each bound ligand colored cyan. 
Relevant inter-atomic distances, including potential hydrogen bonds, are indicated along a 
dashed line. A. Active site of QFR co-crystallized with fumarate. 
 
 
 
(12), and mixed states combining these possibilities. A 3-NP adduct to Arg-A287 
modeled as a 5-membered 2,4,5-triazole structure best explains the density (Fig. 
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29), in close agreement with the crystal structure of avian complex II in complex with 
3-NP (13). Notably, the side chain of adducted Arg-A287 displays an extended 
conformation when compared to the position of Arg-A287 from citrate bound QFR 
(PDBID: 2B76; (17)). This results in a 2.8 Å displacement of the  uanidine group 
toward the FAD. An electrostatic contact between the terminal carboxylate of 3-NP 
and the N5 of FAD stabilizes the adduct. Further, the triazole ring makes putative 
hydrogen bond contacts to three side chains in the active site, with likely hydrogen-
bonding contacts between the NH1 of the adduct and the Oε1 atom on Gln-A230, 
between the NH2 of the adduct and the Oε1 carbonyl atom on Glu-A245, and 
between the N13 of the adduct and the Nh2 of Arg-A390.  
While the structure of the FrdA E49Q variant of QFR in complex with 3-NP 
demonstrates that the binding mode is distinctly different from that of fumarate, 
intriguingly, the addition of 3-NP to QFR induces changes to the optical spectrum 
that are similar to those observed with the addition of fumarate, with peaks 
appearing at 400 nm and 500 nm (Fig. 30). 
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Figure 30. Optical difference absorption spectroscopy of QFR after the addition of ligands. 
Spectra are the difference between the spectrum of the enzyme after addition of each ligand 
and the spectrum of the oxidized enzyme. The spectra are  
colored blue for fumarate, green for oxaloacetate, purple for glutarate, orange for citrate, 
black for 3-nitropropionate and red for malonate. 
 
 
 
This observation is consistent with previous suggestions that 3-NP could act as 
an alternative substrate for complex II enzymes (8, 12).  Therefore to determine 
whether catalytic oxidation or reduction of 3-NP takes place during adduct formation, 
the optical and catalytic properties of the 3-NP and E. coli QFR interaction were 
investigated over time.  Upon addition of an equimolar ratio of 3-NP to wild-type E. 
coli QFR, 3-NP induces optical changes in the spectrum of activated QFR (Fig. 31). 
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The time course of these optical changes matches the change in catalytic activity, 
suggesting that 3-NP is, indeed, a substrate of QFR and that oxidation by FAD forms 
the species that attacks Arg-A287 to result in the formation of the 3-NP-Arg-A287 
adduct.  No further optical changes due to FAD interaction with a ligand nor oxidase 
activity was observed upon addition of a second equimolar dose of 3-NP.  This 
indicates that a single catalytic turnover of QFR is a requirement for formation of the 
3-NP-Arg adduct. 
To determine whether catalytic oxidization or reduction of 3-NP takes place during 
adduct formation, the optical and catalytic properties of the 3-NP and E. coli QFR 
interaction were investigated over time.  Upon addition of an equimolar ratio of 3-NP 
to wild-type E. coli QFR, 3-NP induces optical changes in the spectrum of activated 
QFR (Fig. 31). 
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Figure 31. Optical spectrum following the reduction of FAD (orange) or consumption of 
DCIP (dark red) following 3-NP addition. Activated QFR (~5 µM) was added to 50 mM BTP 
pH 8.0, 30oC.  3-NP (0.2 mM final conc.) was added from a pH 10.0 solution and changes in 
the optical spectrum were monitored at 505-439 nm (upper trace).  (Lower trace) 50 µM 
DCIP was added to the cuvette at the same QFR concentration (5 µM) and reduction of 
DCIP was monitored at 600 nm upon addition of 3-NP from the pH 10 solution.  The arrow in 
both the upper and lower trace indicates that the addition of a second equivalent of 3-NP did 
not cause additional spectral changes indicating that one equivalent of 3-NP is sufficient to 
inhibit the enzyme.  Note, the loss of enzyme activity corresponds to a 1:1 molar ratio of 3-
NP to QFR. 
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Figure 32. Identification of the 3-NP adduct and a proposed mechanism for its formation. 
A. Tandem mass spectrum (MS/MS) from analysis of fragmentation of the YMELGPR*DK 
peptide adducted to 3-NP. B. An MS/MS/MS (MS3) spectrum of the –CO2 neutral loss 
fragment isolated from 3-NP adducted peptide fragmentation (m/z 574.5 from A). C. 
Tandem mass spectrum obtained from analysis of fragmentation of the YMELGPR*DK 
peptide adducted to 15N labeled 3-NP. D. An MS3 spectrum of the –CO2 neutral loss 
fragment isolated from the 15N labeled 3-NP adducted peptide fragmentation (m/z 575.1 
from B). 
 
 
The time course of these optical changes matches the change in catalytic activity, 
suggesting that 3-NP is, indeed, a substrate of QFR and that oxidation by FAD forms 
the species that attacks Arg-A287 to result in the formation of the 3-NP-Arg-A287 
adduct.  No further FAD reduction nor catalytic inhibition was observed upon 
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addition 
of a second 
equimolar dose of 3-NP.  This indicates that a single catalytic turnover of QFR is a 
requirement for formation of the 3-NP-Arg adduct. 
Verification of the chemical identity of the 3-NP adduct by mass spectrometry– The 
location of the 3-NP adduct was verified using LC-MS/MS of trypsinized FrdA 
pretreated with 3-NP.  The 3-NP adducted peptide was identified as a doubly 
charged 596.3 m/z ion with 3-NP adduction with Arg-A287 (Fig. 32). 
Further fragmentation identified the neutral loss of CO2 in the MS3 spectrum (Fig. 
4C) strongly suggesting that the adduct is oriented with the nitro group coupled to 
Arg-A287. Since direct coupling of a nitroalkane and amine is rare and elimination of 
nitrous acid (HNO2) is much more favorable, it was important to determine 
unambiguously whether the nitrogen of 3-NP was incorporated into the triazole. 15N 
labeled 3-NP (98% 15N) was synthesized and the mass spectral analysis was 
repeated. The MS-MS and MS3 analyses exhibited a shift of 1 Da for multiple 
fragment ion peaks, demonstrating incorporation of 15N into the triazole adduct (Fig. 
4B,D).  
Structural basis for inhibition by glutarate– Increased systemic glutarate levels have 
been correlated with decreased complex II activity in vivo (7), but have not 
previously been shown to inhibit the enzyme directly.  Activity of QFR was measured 
in the presence and absence of glutarate, which demonstrates that this 
dicarboxylate acts as a competitive inhibitor with a Ki of 1.9 mM (Table 3). 
 
 Km, mM Ki, mM 
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Table 5. Comparison of the apparent affinity values of dicarboxylates to E. coli QFR. * ref. in 
(17). 
 
 
The structure of QFR in complex with glutarate shows a torsioned conformation 
of the glutarate (Fig. 2D). The angle between the dicarboxylates is 87°, larger than in 
the fumarate co-structure. In this binding mode, the torsion is distributed along a 
greater number of bonds, and the C2 atom bends away from the rest of the ligand, 
causing the C2-C3 and C3-C4 bonds to buckle outward from the FAD. As a result, 
none of the carbon-carbon bonds of glutarate lie along the C(4a)-N5 of the FAD 
isoalloxazine ring. Glutarate does not induce changes in the FAD optical difference 
spectrum (Fig. 30), which supports the hypothesis that the alignment of a bond along 
the C(4a)-N5 bond of FAD underlies these spectral changes. Stabilizing glutarate in 
this conformation are 5 putative hydrogen-bonding contacts (Fig. 33). 
 
Fumarate 0.02*  
Succinate 0.5*  
Oxaloacetate     0.0003* 
Malonate     0.025* 
Citrate    20 
Glutarate     1.9 
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Figure 33. Glutarate binding to the active site. The active site of QFR is shown with nitrogen 
atoms colored blue, oxygen atoms colored red, carbons from the protein colored grey, 
carbons from the FAD colored yellow, and carbons from each bound ligand colored cyan. 
Relevant inter-atomic distances, including potential hydrogen bonds, are indicated along a 
dashed line. A. Active site of QFR co-crystallized with fumarate. 
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Docking calculations– Ligand docking calculations in Glide resulted in ligand poses 
consistent with the experimentally observed binding conformations. From these 
binding poses, an overall binding score was calculated with energetic contributions 
from internally calculated coulombic interactions, hydrogen bonding interactions, and 
van der Waals interactions (Table 6). 
 
 
Table 6. Binding scores of ligands to the E. coli QFR as calculated in Glide XP 
 
 
Surprisingly, these simulations predict that fumarate binds with the least 
favorable coulombic interactions of all ligands tested and the second least favorable 
electrostatic interactions. However, the calculated van der Waals interactions of 
fumarate were more favorable than all other ligands tested. The opposite was true in 
the case of the larger molecule glutarate, which was calculated to have the most 
favorable electrostatic and hydrogen bonding interactions but the least favorable 
calculated van der Waals interactions. Citrate binding was also predicted to show 
unfavorable van der Waals contacts, likely leading to the lowest experimentally-
determined apparent affinity of all the ligands tested (Table 6). Oxaloacetate binding 
Ligand Total Score H-bonding Coulombic Van der Waals 
Fumarate -2.39 -3.9 -24.1 -7.4 
Oxaloacetate -4.37 -3.9 -21.8 -12.1 
Glutarate -10.6 -4.3 -23.6 -12.7 
Citrate -8.49 -2.8 -16.3 -11.1 
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energy was not accurately predicted by the Glide algorithm, which does not take 
charge transfer interactions into account. 
 
 
Discussion 
Complex II enzymes must perform the challenging tasks of activating a kinetically 
stable bond while discriminating between structurally and electronically similar 
substrates.  To identify the properties of QFR important for binding and catalytic 
specificity, structural and spectroscopic analyses of QFR in complex with activatable 
and non-activatable ligands were compared. Our results demonstrate the 
importance of geometric constraints on ligand positioning relative to the FAD 
cofactor in both on-pathway and off-pathway catalysis. 
On-pathway catalysis in QFR– Previous studies demonstrate that QFR reduces 
fumarate to succinate in two distinct steps (33). The first is the rate-limiting hydride 
transfer from FAD to fumarate, and the second is proton transfer from a nearby side 
chain. It is hypothesized that the hydride transfer step of this α,β-dehydrogenation 
reaction is kinetically difficult since the relatively short fumarate lacks extensive 
resonance structures to delocalize developing charges during catalysis. To 
overcome this kinetic stability and catalyze hydride transfer, QFR has been 
proposed to combine multiple geometric and electrostatic mechanisms including: 
substrate polarization (34), active site desolvation, concerted active site 
rearrangement (35), and substrate torsion (31,32).   
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Fumarate binds the E. coli QFR in a torsioned conformation (Fig. 27) similar to 
that observed in co-structures with Wolinella succinogenes QFR (31), and soluble 
homologs of the QFR flavoprotein (32,33), with interdomain rotations likely 
contributing to the torsioning (35). We predict that this torsioning of fumarate may 
facilitate catalysis by allowing improved delocalization of electrons between the C2 
and the carbonyl to narrow the transition state energy barrier.  
Fumarate binding induces the appearance of peaks at 390 nm and 500 nm in the 
FAD optical spectrum. Similar peaks are observed upon the addition of malonate or 
3-NP, but are absent with oxaloacetate, citrate, and glutarate addition (Fig. 30). 
Inspection of the co-structure of QFR with fumarate suggests that alignment of the 
chemically reactive C2-C3 bond parallel to the C(4a)-N5 bond of FAD (Fig. 34) could 
be important for this spectroscopic change and may also be critical for catalysis. 
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Figure 34. Comparison of substrate binding in flavin-containing enzymes catalyzing a,b-
dehydrogenation reactions. Dashes highlight the activated substrate bond and the C(4a)-N5 
bond (FAD), which are aligned. In all the figures, nitrogen is colored blue, oxygen is colored 
red, FAD carbons are colored yellow, and sulfur is colored tan. A. The E. coli QFR co-
crystallized with fumarate. Carbon atoms of the fumarate are colored cyan. 
 
 
 127 
While the alignment of the C2-C3 bond of oxaloacetate with the C(4a)-N5 of FAD 
is also observed in the co-structure (Fig. 37), the additional interaction between the 
FAD and the carbonyl may modify these spectral features in that case. 
A similar alignment of the reactive bond of substrate and FAD is observed in co-
complexes of natural substrates with acyl-coA dehydrogenase (PDBID 3MDE; (36)) 
and D-amino acid oxidase (PDBID 1C0L; (37)), two evolutionarily-unrelated 
flavoenzymes that similarly house FAD-catalyzed α,β-dehydrogenation reactions 
(Fig. 35 C,D). 
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Figure 35. Comparisons of other dehydrogenation ligands. D-amino acid oxidase co-
crystallized with D-alanine (PDBID: 1C0L; (33)). Carbon atoms of D-alanine are colored 
green D. Porcine mitochondrial medium-chain acyl-coA dehydrogenase co-crystallized with 
acyl-CoA (PDBID: 3MDE; (32)). Carbon atoms of acyl-CoA are colored orange. E. In all the 
figures, nitrogen is colored blue, oxygen is colored red, FAD carbons are colored yellow, 
and sulfur is colored tan 
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This conservation of substrate orientation across the isoalloxazine ring of three 
unrelated enzymes suggests that it is ideal for catalysis. Calculations show that the 
FAD HOMO consists largely of a dominant contribution from the N5 and C(4a) 
atoms in lumiflavin (38). Positioning of fumarate parallel to the C(4a)-N5 axis would 
be predicted to maximize the HOMO-LUMO overlap of the fumarate π* anti-bonding 
orbital and the FAD HOMO (Fig. 36), the likely conduit for hydride transfer from the 
N5 position of FAD. 
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Figure 36. A model of the LUMO of fumarate and HOMO of FAD illustrating the predicted 
orbital overlap. Blue and gold represent different phases of the orbital wavefunction. 
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A similar orbital overlap was also proposed to be important for inducing spectral 
changes in FAD of D-amino acid oxidase upon ligand binding to substrate (39). This 
observation is consistent with an orbital steering mechanism, which holds that 
optimal substrate orientation contributes to catalytic efficiency by maximizing 
overlaps of bonding orbitals and minimizing overlaps of non-bonding orbitals (40). 
Subtle geometric changes were shown to be important for hydride transfer upon 
subtle perturbations in iso-citrate dehydrogenase, even after controlling for distance 
changes and electrostatic differences (41), and likely play a role in the catalytic 
mechanism of QFR.  
Following hydride transfer from FAD, a proton is transferred from the side chain 
of an active site residue. In the Shewanella frigidimarina soluble fumarate reductase, 
an elegant combination of site-directed mutagenesis, X-ray crystallography, and 
kinetics demonstrated that an active site arginine structurally equivalent to Arg-A287 
from the E. coli QFR acts as the proton shuttle (34, 42-44). In the E. coli QFR co-
structure with fumarate, a water molecule mediates the interaction between Arg-
A287 and fumarate (Fig. 27). Bound water molecules often act as proton shuttles in 
enzymes, but no on-pathway water molecule has been proposed as a proton donor 
in QFR or other complex II homologs. While our crystal structure leaves open the 
possibility of water-mediated proton transfer in the E. coli enzyme, the location of 
this water molecule may suggest how complex II homologs perform off-pathway 
catalysis.   
Off-pathway catalysis 1: oxaloacetate formation via enzymatic fumarate hydration to 
malate– Oxaloacetate is a tight-binding inhibitor of QFR (3) and its formation might 
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be catalytically induced upon fumarate hydration to malate followed by oxidation to 
oxaloacetate (4). In the structure of oxaloacetate bound to E. coli QFR (Fig. 5B), the 
oxaloacetate carbonyl is oriented parallel to the N5-C(5a) FAD similar to that 
observed in the oxaloacetate co-structure with avian complex II (PDBID 1YQ4; (13)) 
and the malate-like intermediate co-structure with a soluble fumarate reductase from 
Shewenella frigidimarina (PDBID 1QJD; (33)). 
 
 
 
 
 133 
 
 
Figure 37. The E. coli QFR co-crystallized with oxaloacetate. Carbon atoms of the 
oxaloacetate are colored magenta. In all the figures, nitrogen is colored blue, oxygen is 
colored red, FAD carbons are colored yellow, and sulfur is colored tan.  
 
 
The planar orientation of oxaloacetate relative to FAD resembles that of 
fumarate, especially in relation to the similar positioning of the C2-C3 bond in 
fumarate and oxaloacetate (Fig. 34 and 36). Importantly, spectroscopic 
characterization in avian complex II has shown that fumarate can undergo a simple 
hydration reaction along the C2-C3 double bond to yield malate (5). This is 
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corroborated by previous attempts to crystallize QFR homologs with fumarate, which 
have yielded active site density more consistent with oxaloacetate or malate than 
fumarate (33).  
Intriguingly, only the electron density within the active site of structures of 
Shewanella frigidimarina fumarate reductase (PDBID 1QJD; (33)) and avian 
complex II (PDBID 2H88; (5)) co-crystallized with fumarate at pH 7.2 or greater were 
consistent with the malate-like intermediate.  Conversely, both the E. coli QFR and 
W. succinogenes QFR (PDBID 1QLB; (31) were co-crystallized with fumarate at 
lower pH, and the electron density is consistent with a bound fumarate and a water 
molecule. This may reflect two separate catalytic states in the complex II homologs. 
Under high pH conditions, the proton shuttle may be ionized and the active site is 
shifted into a state that allows for water addition, while lower pH leads to a deionized 
proton shuttle, trapping the water molecule near substrate. While speculative, the 
water molecule bound between fumarate and Arg-A287 in the E. coli QFR (Fig. 2A) 
may identify the location of this attacking group during off-pathway malate formation 
from fumarate. When present, malate can be transformed to oxaloacetate via 
hydride transfer from FAD (4). The orientation of oxaloacetate lends support to a 
model where malate is first oriented correctly along the FAD ring and then activated 
for catalysis in a manner analogous to fumarate activation. It is easy to speculate a 
physiological role for this off-pathway catalysis, since the formation of a tightly 
binding inhibitor could regulate the activity of QFR and other complex II homologs.  
The higher apparent affinity of oxaloacetate compared to fumarate may 
potentially be rationalized by interactions with the FAD ring. The expected HOMO-
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LUMO overlap of the π-bonding orbital from the C2-C3=O conjugate of the enol form 
of oxaloacetate and the LUMO of oxidized FAD could underlie the formation of the 
charge-transfer interaction (Fig. 5E) reflected in the band centered at 550 nm in the 
optical spectrum (Fig. 3) (3). This HOMO-LUMO overlap is somewhat analogous to 
the overlap of the C2-C3 double bond of fumarate with the FAD LUMO, except that 
the oxaloacetate carbonyl may also contribute to the formation of the conjugated-π 
system since the almost planar alignment of the C2-C3-O5 atoms of oxaloacetate 
likely aligns the atomic pz orbitals of these atoms with those of the isoalloxazine ring 
(Fig. 5E). A similar delocalized π-conjugated system has been proposed to underlie 
charge transfer formation during the binding of acetoacetyl-coA in acyl-coA 
dehydrogenase (45). The Glide calculations do not include a term corresponding to 
the formation of a conjugated system. That computational modeling only failed to 
account for binding affinity of oxaloacetate supports a conjugated-π interaction 
contributing to the affinity of oxaloacetate binding. 
Off-pathway catalysis 2: suicide inhibition via covalent adduct formation with 3-
NP– X-ray crystallography and mass spectral analysis suggest that 3-NP addition to 
QFR results in the formation of a 2,3,5-triazole adduct to the likely proton shuttle 
Arg-A287. The formation of a 2,3,5-triazole raises a number of chemical challenges, 
including addition to an unreactive carbon atom and reduction of the nitro functional 
group. The 15N labeled 3-NP experiment (Fig. 32) confirms the presence of nitrogen 
from 3-NP in the adduct, ruling out loss of the nitro group through elimination, which 
is a common reaction for activated nitroalkanes. Instead, we considered pathways 
involving both an overall oxidation of 3-NP and a localized formal reduction and 
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dehydration of nitrogen. It has previously been demonstrated that that the 
dehydrogenation product of 3-NP, 3-nitroacrylate, shows faster inhibition kinetics 
than 3-NP, which suggests that 3-NP is converted to 3-nitroacrylate prior to forming 
a covalent adduct (12). The most parsimonious mechanism of conversion of 3-NP to 
3-nitroacrylate is by the complex II enzyme itself. In a co-crystal structure of 3-NP 
with porcine complex II, a non-covalent binding mode for 3-NP was identified within 
the enzyme active site (14). Dehydrogenation of 3-NP to 3-nitroacrylate, a reaction 
analogous to succinate oxidation to fumarate, can be inferred by the observation that 
FAD oxidizes upon 3-NP addition (Fig. 31). Furthermore, FAD oxidation exactly 
matches QFR inactivation, suggesting that 3-nitroacrylate is the active chemical 
species in adduct formation.   
The 3-nitroacrylate intermediate would be expected to be a powerful electrophile that 
engages arginine in an addition reaction. Furthermore, an induced dipole formed by 
interactions with the polar active site, along with geometric torsion, may further 
activate 3-nitroacrylate for addition by arginine in a manner similar to fumarate 
activation. Optical changes in FAD similar to those seen with fumarate binding are 
observed upon 3-NP binding, suggesting that nonadducted 3-nitropropionate and 3-
nitroacrylate likely produce the same fumarate C2-C3 bond overlap over the FAD 
C(4a)-N5 to further activate the unreactive C2 atom adjacent to the nitro group. 
Upon arginine addition, nitro reduction to nitroso releases a molecule of water.  
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Figure 38. Possible minimal mechanism for formation of the covalent adduct 
between 3-NP and Arg-A287. 
 
 
The reactive intermediate prior to nitroso formation could not be characterized; 
however, it is possible that formation of nitronic acid by resonance from a carbanion 
could facilitate nitro reduction. Nitroso formation provides an opportunity for N-N 
bond formation by addition of the arginine nitrogen to the electrophilic nitroso 
nitrogen. A final dehydration and tautomerization would then provide the observed 
triazole (Fig. 38). 
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In cases where nitroalkanes are converted to amide derivatives, the nitroalkane 
is first transformed to the corresponding ketone or carboxylic acid, resulting in 
cleavage of the carbon-nitro bond. A very recent exception to this is the reaction of 
an α-bromo nitroalkane with an electrophilic amine (a halamine, RNHI) (46). 
However, the carbon-nitro bond is cleaved during this transformation as well. The 
nitroalkane derivatization to a triazole without carbon-nitro bond cleavage suggests 
an unprecedented mechanism in the context of known nitroalkane chemistry. A 
mechanistic hypothesis is advanced (Fig. 38) that is consistent with the experiments 
described above. 
Molecular basis for competitive inhibition– The alignment of an activatable bond 
along the C(4a)-N5 bond of the FAD, as is reflected in the optical difference spectra, 
is a clear requirement for either on- or off-pathway catalysis. This suggests that 
dicarboxylates that do not cause differences in the optical spectrum, such as 
glutarate and citrate, do not align similarly. This is indeed what is supported by our 
data. Glutarate does not show an electronic interaction with FAD, but binds within 
the E. coli QFR active site with torsioned carboxylates and at the same location as 
fumarate (Fig. 2D). However, the increased length and flexibility of glutarate results 
in a binding mode where the alkane chain buckles outward and does not orient any 
bond along the C(4a)-N5 bond of FAD. A similar effect is noticed in the published 
QFR co-structure with citrate (17), where citrate lacks a bond aligned to the FAD ring 
(Fig. 39).  
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Additionally, both glutarate and citrate are predicted to have less favorable steric 
interactions, making them bind less tightly than other QFR ligands (Table 6). That 
neither glutarate nor citrate show an electronic interaction with FAD in optical 
spectra (Fig. 30) is consistent with our hypothesis that alignment of an activatable 
bond parallel to the C(4a)-N5 bond of FAD underlies this spectral change, and offers 
a possible explanation for the lack of catalytic turnover of glutarate or citrate. This 
model is consistent with QFR using orbital steering mechanism where geometric 
constraints of the ligand dictate correct orbital overlap.  
 
 
Conclusions 
The geometric and electronic activation of ligands may be a key factor in 
determining ligand activation and behavior in flavoenzymes. This geometric 
activation controls reactivity in QFR, and predicts that potential substrates for QFR 
and FAD-containing enzymes that catalyze a,b-dehydrogenation reactions may be 
identified by examination of optical difference spectra, which undergo changes upon 
orbital interaction with precisely-oriented ligands.  
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CHAPTER IV 
 
PRELIMINARY STRUCTURAL INVESTIGATION OF A MENAQUINOL:FUMARATE 
REDUCTASE MUTANT THAT STABILIZES A SEMIQUINONE RADICAL 
INTERMEDIATE 
 
 
Abstract 
In Escherichia coli menaquinol:fumarate reductase (QFR) catalyzes conversion of 
menaquinol to menaquinone to support anaerobic respiration with fumarate as the 
terminal electron acceptor. QFR can also catalyze ubiquinone reduction to support 
aerobic respiration when expressed under aerobic conditions. In order to study the 
details of the menaquinone reaction and of ubiquinone binding, the co-structures of 
menaquinone and ubiquinone were determined with a mutant variant of QFR, FrdC 
E29L, which stabilizes the semiquinone intermediate of menaquinone. The co-
structures of substrate analogs heptyl-quinoline N-oxide (HQNO) and atpenin A5 
were also determined with the FrdC E29L variant of QFR. A comparison of the 
menaquinone binding sites and HQNO reveal a possible rearrangement with 
menaquinone binding with menaquinone shifting away from the position of the E29L 
mutation. The ubiquinone co-structure and the atpenin A5 co-structure reveals 
electron density in new binding pocket termed QM. Although the physiological 
relevance of this site awaits verification, a series of ionizable residues lining the 
cavity may provide a possible proton pathway.  
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Introduction 
Menaquinol:fumarate reductase (QFR) catalyzes the concomitant 
interconversion of fumarate to succinate and menaquinol to menaquinone. QFR 
couples the two reactions to catalyze the exchange of electrons between two distinct 
environments: the water-soluble environment of the cytoplasm and the lipid soluble 
environment of the plasma membrane (1). Fumarate reduction takes place at the 
soluble flavoprotein subunit frdA. Menaquinol interconversion takes place in the 
membrane area at the intersection of three domains: the iron protein subunit (frdB in 
QFR) and two integral membrane subunits (frdC and frdD in QFR). Along with 
menaquinol oxidation, QFR can also support ubiquinol reduction (2) when 
genetically manipulated for expression during aerobic conditions, functionally 
replacing the activity of succinate:ubiquinone oxidoreductase (SQR).  
Structural analysis of QFR has revealed that menaquinol binds in two distinct 
pockets termed the QP and QD sites (3). The QP and QD sites are ~27Å away from 
each other, too far for efficient electron transfer, leaving unclear any significant 
biological role for the QD site. An unidentified region of electron density was 
observed between the QP and QD sites, dubbed the QM site, although its activity and 
physiological relevance remain unknown (4). Numerous lines of evidence support 
the QP site as the site of menaquinol oxidation.  EPR experiments support that the 
QP site is located proximally to the [3Fe:4S] cluster on the iron protein subunit (5), 
and it is proposed that electron transfer occurs directly from menaquinol bound at QP 
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and the [3Fe:4S] cluster. Numerous amino acids stabilize menaquinol in the QP site, 
including Lys-B228, Arg-C28, Glu-C29, and Trp-D114.  
Identification and verification of quinone binding and active sites has been 
greatly facilitated with the use of site-specific inhibitors (Fig. 39). In general, two 
classes of QFR and SQR quinone site inhibitors are available: the ubiquinone site-
specific inhibitors atpenin A5 (6,7), carboxin, and 2-thenoyltrifluoroacetone TTFA 
and the nonspecific (i.e. ubiquinone and menaquinone) active site inhibitors such as 
heptyl-quinoline n-oxide (HQNO).  
 
 
 
Figure 39. Quinol site ligands. A. Menaquinol B. Ubiquinone (UQ-4) C. Heptyl 
quinoline N-oxide D. Atpenin A5  
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Crystallographic studies of the menaquinone site show that HQNO binds in 
the QP site (4), consistent with EPR data showing a close interaction between 
[Fe3:4S] and HQNO upon binding and spin-relaxation enhancement (8). Crystal 
structures of SQR bound with AA5 and TTFA find a binding site proximal to the 
[3Fe:4S] site, analogous to QP in QFR but with no sequence identity (7). Although no 
crystallographic ubiquinone has been found bound to SQR, the location of these 
inhibitors is consistent with mutagenesis and EPR showing that the site next to the 
[3Fe:4S] is the likely ubiquinone reduction site (9).  
Mutagenesis and EPR experiments have revealed that menaquinol to 
menaquinone interconversion takes place with formation of a stabilized semiquinone 
radical intermediate (5). Mutagenesis of Glu-C29 to leucine significantly raises the 
pKa of menaquinol oxidation, suggesting that Glu-C29 acts as the likely proton 
acceptor in the first step of the semiquinone formation.  The E29L mutation has also 
been shown to stabilize the life-time of the semiquinone radical intermediate by 100 
fold with EPR. In studies of the E29L mutations and menaquinone, a signal was 
detected at g = 2.04, consistent with the formation of an anionic semiquinone 
intermediate similar to that observed in bovine complex II. This proposed 
semiquinone signal was likely at the QP site due to a spin-relaxation enhancement 
from the [3Fe:4S] cluster (5).   
QFR can also support ubiquinone oxidation in vitro to support aerobic 
succinate oxidation, though in vivo it is not expressed under aerobic conditions (2). 
Although QFR can catalyze ubiquinone oxidation in vitro, a binding site or 
mechanism has not been identified for ubiquinone binding. The E29L mutation did 
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not show a decrease in ubiquinone reduction, suggesting either a separate binding 
interaction at the QP site or a separate binding position (5). 
To study the effects of the QFR E29L mutation on the structure of the QP 
active site and on the binding of menaquinone, ubiquinone-4 (UQ-4), and inhibitors, 
we structurally characterized the binding of these ligands with QFR E29L as well as 
wild-type QFR with atpenin A5 as a comparison. The mechanistic implications for 
semimenaquinone stabilization and ubiquinone binding and catalysis are explored. 
 
Materials and Methods 
 QFR purification –The FrdC E29L variant of the E. coli QFR was produced in 
E. coli strain DW35 (ΔfrdABCD, sdhC::kan) cells containing the pH3 plasmid grown 
under microaerophilic conditions in Terrific Broth medium as previously described. 
Isolated membranes, obtained as described in (10), were suspended in a solution of 
20 mM Tris, 0.1 mM EDTA (pH 7.4) followed by solubilization with C12E9 detergent 
(Anatrace) to a final concentration of 2%. Purification of QFR was performed using a 
three-step chromatography protocol beginning with Q-sepharose anion exchange 
(GE Healthcare), then with POROS anion exchange (Applied Biosystems), followed 
by size exclusion chromatography on a superdex S-200 column (GE Healthcare) as 
described previously (10). Slight modifications were made to the protocol to account 
for the increased instability of the E29L mutant, namely that the second anion 
exchange step was lengthened from an elution gradient of 7 column volumes to 14 
column volumes.  Protein concentration was measured by the bicinchoninic acid 
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method (Pierce) with bovine serum albumin as standard in the presence of 0.05% 
(w/v) C12E9 detergent.  
 Crystallization of the E29L mutant QFR with inhibitors- E29L QFR and 
menaquinone co-crystals were grown in polyethylene glycol 5000, mM magnesium 
acetate, 100 mM citric acid pH 5.8, 0.1% DTT, 0.1mM EDTA at room temperature. 
The E29L QFR and atpenin A5 co-crystals were grown in 13.5% polyethylene glycol 
(PEG) 5000 mono-methyl ether (MME), 80 mM magnesium acetate, 100 mM citric 
acid pH 5.8, 0.1% DTT, and 0.1 mM EDTA at room temperature, and 360 nM 
Atpenin A5. Wt QFR and atpenin A5 co-crystals were grown in 13% polyethylene 
glycol 8000, 25 mM magnesium acetate, 100 mM citric acid pH 5.8, 0.1% DTT, 0.1 
mM EDTA, and 120 nM of atpenin A5  at 22°C. E29L QFR and UQ-4 co-crystals 
were grown with QFR co-purified with 25 µM of UQ-4 in 16.5% polyethylene glycol 
8000, 40 mM magnesium acetate, 100 mM citric acid pH 5.8, 0.1% DTT, 0.1 mM 
EDTA. E29L QFR and HQNO co-crystals were grown with QFR co-purified with 10 
mM of HQNO in 13.5% polyethylene glycol 5000 monomethyl ether, 100 mM 
magnesium acetate, 100 mM citric acid pH 5.8, 0.1% DTT, 0.1 mM EDTA.  
 Crystals were grown using the hanging drop vapor diffusion method. QFR 
crystals formed in the orthorhombic space group P212121 with unit cell dimensions 
shown in Table 6.  Data collection statistics are shown in Table 6 
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Table 7: Data collection and refinement statistics for crystal structures of QFR  
  E29L MQ E29L AA5 WT AA5  E29L HQNO E29L UQ-4 
Wavelength 1.0 Å  1.1 Å  1.1 Å  1.2 Å  1.0 Å 
Beamline SSRL 9-2 APS ID-21 SSRL 9-2 APS ID-21  SSRL 9-2 
Resolution 3.3 Å  3.40 Å  3.10 Å  3.35 Å  3.1 Å 
Completeness  80.2% (73.8%) 92.4% (81.2%) 81.1% (72.1%) 90.0% (84.1%) 92.7% (63.0%) 
I/s  12.8 (2.3) 10.1 (2.5) 10.7 (1.9) 16.1 (4.9) 12.4 (2.0) 
Rsyma  0.097 (0.392) 0.096 (0.333) 0.153 (0.515) 0.100 (0.272) 0.098 (0.389) 
Refinement 
Rcrystb  0.240  0.224   --  0.228  0.240 
Rfree  0.305  0.262  --  0.280  0.281 
RMSD bonds 0.023  0.026  --  0.025  0.034 
RMSD angles 2.304  2.393  --  2.602  2.831 
 
Values in parenthesis indicate statistics for the highest shell. 
A: Rsym = S |Ii - <I>|/SIi where I is intensity, “I” is the ith measurement, and <I> is the weighted mean of 
I. 
b: Rcryst = S ||Fobs| - |Fcalc||/SFpbs. Rfree is the same as Rcryst for a set of data omitted from the 
refinement.  
 
 
 Data collection and processing – Data reduction was performed using the 
programs DENZO (11), SCALEPACK, HKL2000 (12), and the CCP4 suite of 
programs. Since crystals were isomorphous with crystals from known structures of 
QFR (13), rigid body refinement was performed with refmac to obtain an initial model 
and initial phases (14). Wild-type QFR with oxaloacetate bound (later deposited as 
PDBID: 3PQR) was used as a starting model for QFR co-complexed with MQ. The 
already published structure 1KF6 (4) was used for the HQNO, UQ-4, and atpenin-A5 
co-structures with FrdC E29L QFR. Model rebuilding was performed in the molecular 
graphics program COOT (15) while refinement and map calculations were 
performed with Refmac5 in CCP4 and Phenix (16). Molecular representations used 
were created in the program PyMOL (17). 
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Results 
The FrdC E29L variant of QFR was co-crystallized with substrates 
menaquinone, ubiquinone and inhibitors HQNO, and atpenin A5. Preliminary 
electron density allowed for tentative assignment of ligand binding in each co-crystal 
structure and compared to wild-type QFR co-structures. 
Alterations and rearrangements of menaquinone in the FrdC E29L QFR QP 
site – The QFR co-structure with co-purified menaquinone bound showed clear 
density for a menaquinone molecule only at the QP site, and was absent at QD (Fig. 
40).  
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Figure 40. Comparison of electron density of QFR-ligand complexes. The C subunit 
is colored grey and the D subunit colored black. Oxygen atoms are colored red, nitrogen 
atoms are colored blue, and carbon atoms are colored  salmon for menaquinone, orange for 
ubiquinone, yellow for HQNO, and teal for atpenin A5. Electron density is countered as a 
green mesh at 2σ for all structures except for menaquinol, where it is contoured at 1.5σ. A. 
The published structure of wild-type QFR with menaquinol (PDBID:1LOV; (3)) B. The co-
structure of frdC E29L QFR with menaquinol in the QP active site. B. The co-structure of 
frdC E29L QFR with ubiquinol modeled in the QM site. B. The frdC E29L QFR co-struc ture 
with HQNO modeled in the QP active site. B. The co-structure of frdC E29L QFR with 
atpenin A5 modeled in the QM site. 
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In the QP site, menaquinone makes multiple putative hydrogen bonding 
contacts, including from O4 of the menaquinone to Nε1 of Trp-D14 and to of Nζ of 
Lys-B228 (Fig. 41).  
 
Figure 41. Ligand binding in the E29L QFR co-structures. The C subunit is colored 
grey and the D subunit colored black. Oxygen atoms are colored red, nitrogen atoms are 
colored blue, and carbon atoms are colored salmon for menaquinone, orange for 
ubiquinone, yellow for HQNO, teal for atpenin A5, and either grey or black for side chains 
depending on which subunit they are from. Dashes represent distances between atoms in 
angstroms. A. Menaquinol bound in the QP site. B. Ubiquinone (UQ-4) bound in the QM site. 
C. HQNO bound in the QP site. D. Atpenin-A5 bound in the QM site. 
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Figure 42. Superimposition of the altered position of menaquinol binding in E29L 
binding compared to menaquinol bound to wild-type QFR and HQNO bound to wild-type 
QFR. The B subunit is colored green, C subunit is colored grey and the D subunit colored 
black. Oxygen atoms are colored red, nitrogen atoms are colored blue, and carbon atoms 
are colored salmon for menaquinone bound to E29L QFR, yellow for HQNO bound to wild-
type, and white for menaquinol bound to wild-type QFR. The side chains are colored either 
grey or black for side chains depending on which subunit they correspond to. 
 
 
Menaquinone exhibits a shifted position in the active site, shifting 1.1 Å away 
from its position in wt QFR when measured at the distal part of the ring (Fig. 42).  
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A 1.0 Å shift is exhibited at the O1 oxygen, away from the Ala-C29.  The shift 
is towards Lys-B228, and away from Ala-C29; however, this change does not 
significantly alter the distance to the [3Fe:4S] iron sulfur cluster compared to the MQ 
position in wild-type. The shift is consistent with a model proposed where 
menaquinol binds, and then swings around an axis while maintaining hydrogen 
bonds with Trp-D14 and Lys-B228. 
Possible identification of the ubiquinone binding site – The structure of E29L 
QFR co-complexed with UQ-4 exhibited strong density in a pocket located near the 
center of the membrane in the integral membrane subunits (Fig. 40C). This 
observation is consistent with the presence of previously unidentified electrons 
density observed in co-structures of HQNO with wild-type QFR. The binding pocket 
is made by the intersection of two helices each from subunit C and subunit D. 
Further experiments have to be performed to identify this as a true ubiquinone 
binding site. A cautious interpretation of the electron density allowed for the 
preliminary modeling of UQ-4 into the active site. UQ-4 was tentatively modeled in 
the density, and exhibits a distance of 8.6 Å from the QP site and 14.5 Å from the QD 
site, both within the expected 15Å limit for biologically relevant electron transfer (Fig. 
43). 
 
 
 
 
 158 
 
 Figure 43. Relationship of the [3Fe:4S] iron-sulfur cluster, QP, QM, and QD sites to 
one another. The B subunit is colored green, C subunit is colored grey and the D subunit 
colored black. Oxygen atoms are colored red, nitrogen atoms are colored blue, iron colored 
brown, sulfur atoms colored tan, and carbon atoms are colored salmon for menaquinone 
bound to E29L QFR, and orange for ubiquinone.  
 
 
The UQ-4 model makes several contacts in the highly polar pocket. These 
include putative hydrogen bonds from O1 of UQ4 to the γ-hydroxyl of Ser D24 and  
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Figure 44. Hypothetical proton pathway between the QD and QM sites. The C subunit 
is colored grey and the D subunit colored black. Oxygen atoms are colored red, nitrogen 
atoms are colored blue, and carbon atoms are colored salmon for menaquinone bound to 
E29L QFR and orange for ubiquinone. The side chains are colored either grey or black for 
side chains depending on which subunit they correspond to. Dashes represent distances 
between atoms in angstroms. 
 
From the O4 oxygen of UQ-4 to the γ-carbonyl of Thr-C31, the η1 of Arg-D81 
and the Nδ1 of His-D82 (Fig. 41C). Interestingly, His-D82, when mutated, leads to 
decreased QFR reduction of ubiquinol, supporting a role for this residue in the 
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ubiquinol reduction mechanism (2) . A series of protonatable residues extends from 
the QM site to the QP, including His-D82, Arg-D81, and Glu-C29, suggesting a 
possible route for proton transfer between the two sites (Fig. 44). Numerous 
pathways for UQ entry into the QM site are possible, including entry from the QP site, 
entry from the QD site, or entry laterally from the membrane. The later seems 
unlikely, since it would require lateral movement of two helices. The most likely 
pathway is from the QP site, which would require the movement of Arg-D83. This 
hypothetical movement would make an internal cavity that then would provide a 
binding site for UQ. 
 HQNO binding is shifted slightly in the E29L QFR variant – The co-structure 
of HQNO with E29L shows a slight 0.9Å difference in position compared to HQNO in 
the wild-type enzyme.  In the E29L QFR co-structure, HQNO moves towards Lys-
B228 and away from Leu-C29, similar to the change observed in the comparison of 
menaquinone complexed with QFR E29L and wt. The ring of HQNO moves laterally 
sideways, with little change of distance to the iron sulfur cluster. The movement is 
consistent with that proposed and may be on-pathway to position the 
menasemiquinone into an additional binding pocket for catalysis.  
 Atpenin A5 binds in the QM site – The co-structure of E29L QFR and atpenin 
A5 reveals electron density in the QM region. Atpenin A5 makes similar putative 
hydrogen bonding contacts as UQ (Fig. 41D). Notably, there is a minor shift in the 
binding position of atpenin-A5, towards the Thr-C31 by 1.2Å.   
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Conclusions and Future Directions 
 The examined co-crystal structures of the QFR ligands with E29L QFR 
allowed for tentative assignments of the electron density. More work remains to 
positively confirm the location of these ligands. Future directions for this work include 
further refinement of the co-complexes, and mutation of residues along the QM 
pocket to test the effects of UQ-4 binding and turnover. Future work will aim to 
discover what the importance of menaquinone rearrangements is, the significance of 
the QM pocket, and what the proton pathway is to the QM site. 
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CHAPTER V 
 
PURIFICATION OF A STABILIZED MENAQUINOL:FUMARATE 
OXIDOREDUCTASE AND FLIG CO-COMPLEX 
 
Introduction 
Locomotive bacteria such as Escherichia coli can sense their external 
environments and respond by moving away or towards a stimulus. This is 
accomplished by modulation of the activity of the flagellar motor, a large megadalton 
complex with a tail-like appendage called a flagellum (1). External and internal 
signaling cues bias the direction of flagellar spin to either clockwise or 
counterclockwise. Counterclockwise rotation propels the bacterium forward while 
clockwise rotation results in a tumbling behavior, which leads to a random 
reorientation of the cell. Alternating series of “runs” and “tumbles” biased by 
signaling cues allow for a mechanism to control the overall direction of travel.  
 The direction of bacterial spin is controlled through the activity of the switch 
complex, a series of three proteins – FliG, FliM, and FliN – that, through an unknown 
mechanism, respond to a signal and switch direction of rotation. It has been 
proposed that this switching occurs through a conformational change in FliG, 
causing a synchronized alteration of the alignment of positively and negatively 
charged residues (2-4). Many of the signals biasing flagellar spin are sensed 
extracellularly, by receptors such as CheA (5). Upon activation, these receptors 
activate histidine kinase cascades, activating signaling proteins such as CheY (6). 
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For a number of years, the dicarboxylates fumarate and oxaloacetate have been 
understood to alter the rotation of the flagellar motor, biasing it towards clockwise 
rotation (7). The effect of fumarate binding on flagellar spin was discovered to be 
mediated by a direct interaction between quinol:fumarate reductase (QFR) and FliG 
(8). This signaling event was found to be separate from the activity of QFR in its 
bioenergetic capacity, and may be mediated directly by conformational changes that 
are thought to occur in QFR upon ligand binding (9). 
 To study the interaction between QFR and FliG, we have attempted to co-
crystallize a complex between QFR and FliG.  Initial attempts to obtain the QFR-FliG 
complex structure began with an attempt to identify conditions that would maximally 
stabilize the complex on size-exclusion chromatography. Following purification, 
numerous crystal conditions were screened.  
 
Materials and Methods 
Full length E. coli FliG in the pEWG1 vector (8) was grown from a starter culture for 
~8hrs in 5ml LB with 0.1mg/ml ampicillan and 0.034 mg/ml chloramphenicol, which 
is used to inoculate 500ml LB overnight with appropriate antibiotics. The inoculum is 
then distributed among 6 1L flasks of LB media with an inoculum size of 50-80ml 
culture per 1 L LB with 0.1mg/ml ampicillan and 0.034 mg/ml chloramphenicol. The 
cells are grown at 37C° until the OD600 is ~0.5 (~2 hrs). The cells are then induced 
with 1mM IPTG and grown until the OD600 reaches ~2.0 (~2-3 hrs) and harvested by 
centrifugation at 5000g for 15 min. 
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Cells were lysed using sonication in lysis buffer containing 50mM NaH2PO4, 
300mM NaCl, and 10mM imidazole + 3 inhibitor tablets/50ml buffer + DNase + 
RNase. The lysate was then cleared with an ultracentrifuge at 45000rpm in a Ti70 
rotor for 40min at 4C°. Next, the supernatant is filtered and applied to Talon resin or 
to Ni Hitrap column. The lysate and resin mixture is incubated at 4C° for 45min while 
rotating. To isolate the protein, the resin is washed with 50-100 bed volumes of 
buffer A. FliG is then eluted with buffer B and immediately diluted into buffer A 
without imidazole and concentrated in a 10 kDa cutoff Amicon filter at 2500-3000g 
(Fig. 45).  
 
 
 
Figure 45. SDS-PAGE gel of purified FliG. Lane 1: Ladder. Lanes 2-4: successive elution of 
Ni2+ affinity resin. 
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To isolate the QFR/FliG complex, FliG is added to QFR (purified as in (10)) in a 
1:9 molar ratio of QFR/FliG with 20mM tris pH 7.4, 0.02% do-decyl maltoside added 
to a total volume of 5ml. The mixture is then dialyzed against ~150 ml buffer D for 2-
3 hrs. The QFR/FliG mixture is concentrated to ~500ul on a 50kDa cutoff Amicon 
filter and loaded on a superdex gel filtration column (Fig. 46). 
 
Figure 46. Gel filtration chromatogram of QFR/FliG run and corresponding SDS-PAGE gel. 
 
 
Results and future directions 
The QFR/FliG complex was applied to several crystallographic screens in 0.05% 
Thesit, 0.02% DDM, and 5mM DM. A total of ~3600 crystallization conditions were 
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tested. Initial attempts to purify and crystallize the complex resulted in crystals that 
diffracted to ~3.4 Å resolution (Fig. 47).  
 
Figure 47. Preliminary crystals obtained from QFR/FliG mixture. 
 
 
However, although QFR was identified in the crystallographic electron density, FliG 
was unable to be located. Attempts to verify the incorporation of FliG into the 
crystals with mass spectrometry were unsuccessful. Size exclusion chromatography 
to verify the stability of the QFR/FliG complex showed that the complex started to 
break down ~1hr after formation. (Fig. 48). Further attempts were made to determine 
the optimal purification conditions for both FliG alone and in complex with QFR when 
isolated with size-exclusion chromatography (Table 8). Though it was difficult to 
obtain a quantitative measure of stability, high pH, dicarboxylate additives, and  
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Figure 48. Size exclusion chromatograms of QFR/FliG complex immediately after dialysis 
(run 1) and of run 1 reapplied to the gel-filtration column (run 2). A407 measures the 
absorbance from the covalently linked FAD cofactor. 
 
 
 
 
 
Buffer Detergent Additive FliG alone QFR/FliG 
complex 
20mM Tris pH 7.4 0.05% Thesit - Unstable Stable 
20mM Tris pH 7.4 0.02% DDM - - Stable 
20mM Tris pH 7.4 5mM DM - - Stable 
20mM Bis-Tris pH 6.0 0.02% DDM - - Unstable 
20mM Tris pH 9.0 0.02% DDM - - Stable 
20mM KPi pH 7.4 0.02% DDM - Unstable Stable 
20mM Tris pH 7.4 0.02% DDM 100mM NaCl Stable Stable 
20mM Tris pH 7.4 0.02% DDM 300mM NaCl Stable Stable 
20mM Tris pH 7.4 0.02% DDM 10mM MgSO4 - Stable * 
20mM Tris pH 7.4 0.02% DDM 10mM 
Oxaloacetate 
- Stable * 
20mM Tris pH 7.4 0.02% DDM 10mM 
fumarate 
- Stable 
Table 8. Assessment of FliG or FliG/QFR stability with gel-filtration chromatography. 
DDM=Β-Dodecyl maltoside DM=Decyl maltoside KPi = potassium phosphate *= especially 
stable condition 
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MgSO4 seemed to stabilize the complex. QFR addition to FliG seemed to greatly 
stabilize FliG in solution. 
 
Conclusions 
Since the stability of QFR alone has been well characterized, new conditions to 
stabilize both FliG alone and FliG bound to QFR have been sought. The complex 
was seemingly formed and stabilized equally well with all the detergents tested and 
buffers tested, except for Bis-Tris pH 6.0 (Table 8). The keys for stability seem to be 
ultracentrifugation of the lysate (the lack of which resulted in extremely dirty preps – 
data not shown), removal of imidazole, dialysis, and saturation of QFR with FliG. 
Future work has been planned to try a multifaceted approach to stabilize the 
QFR/FliG complex, including screening with a virial coefficient stability screen (11), 
using lipid bicelles (12), and attempting crystallization with shortened or mutant FliG 
constructs (3,4,13).  
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CHAPTER VI 
 
SUMMARY AND SYNOPSIS 
 
Summary 
The development of methods to probe integral membrane protein structure 
(1) has allowed the chemical probing of function of many key enzymes. The initial 
structures of the respiratory complexes (2-7) provided a foundation to ask detailed 
mechanistic questions of how these key enzymes function and provide answers 
satisfying on a physical chemical level, helping to bridge the study of membrane 
protein biology with the realm of chemistry. With the initial QFR (2,8), SQR (9), and 
eukaryotic complex II structures (10,11) in hand, the opportunity arose to learn 
crucial details about flavin chemistry, electron transfer, quinol interconversion, 
reactive oxygen species formation, and toxin inhibition. It is difficult to overstate the 
value of these questions, since they can lead to insight into such diverse processes 
as tumor formation (12), neurotoxicity (13), and aging (14)  – all areas where 
alterations of complex II function has been shown to contribute. The work presented 
in this dissertation adds to the body of knowledge concerning complex II function in 
general and Escherichia coli QFR function in particular by examining four distinct 
areas: dicarboxylate catalysis, inhibition and off-pathway catalysis, quinone 
interconversion, and signaling.  
   In chapter one of this work, we investigated the relevance of an active site 
loop for formation of the fumarate to succinate transition state (15). Fumarate 
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hydrogenation presents a challenge for QFR due to the relative kinetic stability of 
hydride transfer owing to the small size of fumarate and succinate. To overcome this 
challenge, the QFR dicarboxylate active site stabilizes fumarate in a torsioned, 
partially charged conformation (8,16). Chapter one presents evidence that this 
conformation comes about in part due to the concerted activity of two threonine 
residues, Thr-A234 and Thr-A244. Thr-A234 interacts with the active site proton 
shuttle, altering its pKa and possibly linking its protonation state to the 
conformational state of the dicarboxylate active site. Difference absorbance 
spectroscopy showed that a Thr-A234 mutation to alanine abrogated proper 
positioning of ligand, which corroborated loss of enzyme activity and which was 
recapitulated with a shift of solution pH.  Mutation of Thr-A244 to alanine similarly 
resulted in a loss of activity; however, this was the first mutation to result in a 
decrease of the second order rate constant (kcat/KM). This was rationalized by the 
position of Thr-A244, which donates a hydrogen bond to fumarate in a position ideal 
for attainment of the stabilized, twisted intermediate. Taken together, these two 
mutations allowed the proposal of a model where domain movements torsion the 
substrate upon binding to 1) facilitate attainment of the transition state and 2) to act 
as a control mechanism that only brings in necessary catalytic residues for catalysis 
upon formation of a fully closed and aligned active site.  
 The second chapter further investigated the result of the twisting mechanism 
on the ligand and its potential implication for inhibition and side-product formation.  A 
trend was observed between structures of non-activatable and activatable QFR 
ligands. Those ligands that were potential targets of a QFR reaction, such as 
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fumarate or oxaloacetate, all were torsioned in such a way that an activatable bond 
was aligned almost exactly parallel with the C(4a)-N5 bond of FAD. Those that were 
not activated, the inhibitors glutarate and oxaloacetate, lacked this positioning, 
probably due their inherent geometry. The activatable ligands further shared the 
characteristic of an electronic interaction with FAD that shifts its optical properties, 
while the non-activated ligands did not. We proposed that this was possibly due to 
an orbital-steering mechanism, where two frontier orbitals have to be positioned 
almost exactly to maximize their overlap. The orbital-steering theory holds that 
enzymes are evolutionarily tuned to maximize HOMO-LUMO overlap and that slight 
structural perturbations can have dramatic effects on enzyme activity (20,21). It was 
proposed that the orbital steering mechanism may also contribute to formation of a 
covalent adduct with 3-nitropropionate, and optical spectroscopy and mass 
spectrometry were used to propose a suicide inactivation mechanism. The reaction 
is, as far as is evident, unique in nature and adds another dimension to arginine 
chemistry. 
 The third chapter examined the activity of an entirely distinct active site, the 
quinol interconversion site. Here, we examined the structural details of interaction 
between a mutant, QFR FrdC E29L, with the substrates menaquinone and 
ubiquinone as well as the inhibitors heptyl quinoline n-oxide (HQNO) and atpenin 
A5. The FrdC E29L mutation was shown with EPR to stabilize a semiquinone radical 
intermediate of menaquinone in the active site (17). Although the structures are still 
preliminary, a very cautious initial interpretation revealed a number of interesting 
features. First, menaquinone and its analog, HQNO, bind in slightly altered positions 
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form those seen in the wild-type co-structures (2,18). The altered binding may reveal 
a reaction mechanism were menaquinol binds two or more conformations en route 
to menaquinone formation. Investigation of ubiquinone binding revealed the 
unexpected increase of electron density in a region called the QM region, as did the 
ubiquinone analog atpenin A5. In the QM site, the preliminarily modeled ubiquinone 
would make multiple stabilizing interactions, as well as interactions with possible 
catalytic residues that could be linked by a proton shuttle to the QP site. Although 
this is highly speculative, it would be interesting to test the possibility of linked 
menaquinone and ubiquinone catalysis. A great deal of work remains to be done to 
refine the co-structures, to verify the ligand positions, and to mutate residues 
possibly important to catalysis. This will help clarify the significance of the 
menaquinone rearrangement, the validity of the QM ubiquinone site, and any 
physiological relevance of the interplay between the QM and QP sites.  
 Finally, very preliminary work was undertaken to study the role of QFR not in 
its bioenergetic capacity, but instead as a signaling molecule. Previous work has 
shown that QFR can directly mediate changes in the direction of flagellar spin upon 
fumarate binding through a direct interaction with the flagellar protein FliG (19). To 
investigate the structural rearrangements that might underlie this signaling, 
especially given that enzyme dynamics may be important for fumarate catalysis, the 
stabilization and crystallization of the QFR/FliG complex was performed. Initial 
success with purification of a 1:1 QFR/FliG complex led to a series of crystallization 
attempts. Upon screening ~3600 crystallization conditions, two crystallization 
conditions were found, one of which yielded diffraction quality crystals. Despite 
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obtainment of a quality dataset, a molecular replacement solution with FliG was 
elusive. Attempts with mass-spectrometry to reveal the nature of the crystals were 
inconclusive, due to the small size of the crystals. Further characterization revealed 
that, although the QFR/FliG complex can be formed, it is unstable. Further work will 
focus on stabilizing FliG alone, then FliG with QFR. 
 In these studies, the capacity of QFR to perform multiple tasks was explored. 
In all, the structural details of catalysis of five types of chemical reactions were 
investigated at two known and one possible active sites. Additionally, preliminary 
work was performed to study the role of QFR not as an enzyme but as a receptor. 
Taken together, this speaks to the remarkable flexibility and utility of this 
evolutionarily ancient class of enzymes. 
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